- 1 Title: Integrating genetic regulation and single-cell expression with GWAS prioritizes causal genes
- 2 and cell types for glaucoma
- 3

4 Authors:

- Andrew R. Hamel^{1,2,3}, Wenjun Yan^{4,*}, John M. Rouhana^{1,2,3,*}, Aboozar Monovarfeshani^{4,*}, Xinyi
 Jiang^{5,6}, Puja A. Mehta^{1,2,3}, Jayshree Advani⁷, Yuyang Luo^{1,2,3}, Qingnan Liang⁸, Skanda
 Rajasundaram^{2,9,10}, Arushi Shrivastava^{1,2,3}, Katherine Duchinski^{1,2,3}, Sreekar Mantena^{1,11}, Jiali
 Wang^{1,2,3}, Tavé van Zyl^{4,12}, Louis R. Pasquale¹³, Anand Swaroop⁷, Puya Gharahkhani¹⁴, Anthony
 P. Khawaja¹⁵, Stuart MacGregor¹⁴, International Glaucoma Genetics Consortium (IGGC), Rui
- 10 Chen⁸, Veronique Vitart⁵, Joshua R. Sanes⁴, Janey L. Wiggs^{1,2,3}, Ayellet V. Segrè^{1,2,3,#}
- 11

12 Affiliations:

- ¹Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA
- 14 ²Department of Ophthalmology, Harvard Medical School, Boston, MA
- 15 ³Broad Institute of Harvard and MIT, Cambridge, MA.
- 16 ⁴Department of Molecular and Cellular Biology and Center for Brain Science, Harvard University,
- 17 Cambridge, MA, USA
- ⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh,
- 19 UK
- 20 ⁶Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, The
- 21 University of Edinburgh, Edinburgh, UK
- ⁷Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of
- 23 Health, Bethesda, Maryland, USA
- ⁸Department of Molecular and Human Genetics, Baylor College of Medicine, TX
- 25 ⁹Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK
- 26 ¹⁰Faculty of Medicine, Imperial College London, London, UK
- 27 ¹¹Harvard/MIT MD-PhD Program, Harvard Medical School, Boston, MA
- 28 ¹²Department of Ophthalmology and Visual Sciences, Yale School of Medicine, New Haven, CT
- ¹³Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 30 ¹⁴QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4029, Australia
- ¹⁵NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL
- 32 Institute of Ophthalmology, London, UK
- 33 * Co-second authors, these authors contributed equally
- 34 [#] Correspondence to be addressed to Ayellet V. Segrè: <u>ayellet_segre@meei.harvard.edu</u>

35

36 Abstract

37

Primary open-angle glaucoma (POAG), characterized by retinal ganglion cell death, is a leading 38 39 cause of irreversible blindness worldwide; however, the molecular and cellular causes are not well 40 understood. Elevated intraocular pressure (IOP) is a major risk factor, but many patients have 41 normal IOP. Colocalization and Mendelian randomization analysis of >240 POAG and IOP GWAS 42 loci and of overlapping eQTLs and sQTLs in 49 GTEx tissues and retina prioritized causal genes 43 for 60% of loci. These genes were enriched in pathways implicated in extracellular matrix 44 organization, cell adhesion, and vascular development. Analysis of single-nucleus RNA-seq of glaucoma-relevant eye tissues revealed that the colocalizing genes and genome-wide POAG and 45 46 IOP associations were enriched in specific cell types in the aqueous outflow pathways, retina, optic 47 nerve head, peripapillary sclera, and choroid. This study nominated IOP-dependent and 48 independent regulatory mechanisms, genes, and cell types that may contribute to POAG 49 pathogenesis.

50

51 Introduction

52

53 Primary open-angle glaucoma (POAG) is the leading cause of irreversible blindness worldwide among people over the age of 55¹. It is characterized by progressive optic neuropathy. 54 55 caused by the gradual death of retinal ganglion cells (RGCs) that transmit visual information from the outer retina to the brain via the optic nerve (myelinated RGC axons)². Elevated intraocular 56 57 pressure (IOP) is a major risk factor for POAG³ and is primarily caused by decreased outflow of the 58 aqueous humor from the ocular anterior segment. Decreased outflow may be due to abnormal 59 function of structures in the anterior segment of the eye, consisting of the trabecular meshwork (TM)⁴ and Schlemm's canal (SC)⁵ in the conventional outflow pathway, and the ciliary muscle and 60 iris in the uveoscleral (unconventional) pathway⁶. However, about one third of patients with POAG 61 display optic nerve degeneration in the absence of abnormally high IOP measurements (normal 62 tension glaucoma (NTG))⁷. Conversely, many people with elevated IOP do not develop glaucoma, 63 64 suggesting that other processes, including increased RGC susceptibility to normal IOP, might also 65 lead to optic nerve damage. Currently, neuroprotective therapies are lacking, and medications that reduce IOP have limited effectiveness². Gaining a better understanding of the molecular and 66 67 cellular causes of POAG in the anterior and posterior segments of the eve could suggest novel 68 therapeutic targets.

69 A recent multi-ethnic genome-wide association study (GWAS) meta-analysis of 34,179 70 POAG cases and 349,321 controls of European, Asian, and African ancestries identified 127 risk loci associated with POAG⁸, explaining ~9% of POAG heritability, and a meta-analysis of the 71 European subset identified 68 POAG loci⁸, some of which were not uncovered in the cross-ancestry 72 73 meta-analysis. Furthermore, a GWAS meta-analysis of IOP performed on 139,555 individuals, 74 primarily of European descendant⁹, has identified 133 independent associations in 112 loci, largely overlapping with two other studies^{10,11}. The IOP variants' effect sizes and direction of effect are 75 highly correlated with their effect on POAG risk^{8,9}, and together they explain 9-17% of IOP 76 77 heritability. Vertical-cup-to-disc ratio (VCDR), central corneal thickness, and corneal hysteresis, a 78 measure of the viscoelastic damping of the cornea, have also been associated with POAG risk, and large GWAS meta-analyses have uncovered 70-200 genetic associations for these traits¹²⁻²³. 79

80 Identifying putative causal genes and cell types underlying the genetic associations with 81 POAG and its related traits is challenging. As with other complex traits, a majority of associated variants lie in noncoding regions and are enriched for regulatory effects²⁴⁻²⁶. Due to linkage 82 83 disequilibrium (LD), the discovered associations typically tag multiple variants and genes, making 84 it hard to pinpoint the implicated causal gene(s) from sequence alone. Furthermore, genetic regulatory effects in relevant ocular tissues are limited, reported to date only in retinal tissues^{27–30}. 85 86 and have not yet been detected at cellular resolution in other parts of the eye. Nevertheless, through 87 single-cell or single-nucleus RNA-sequencing (sc/snRNA-seq), human cell atlases and cellular 88 level transcriptomes have been generated for various non-diseased eye tissues relevant to POAG pathogenesis, including reting^{31–33}, the aqueous humor outflow pathways^{34,35}, six tissues in the 89 anterior chamber³⁶, and the optic nerve head (ONH), where RGCs pass to exit the eye, the optic 90 nerve, and surrounding posterior tissues³⁷. Using a method we recently developed, ECLIPSER^{38,39}, 91 92 we show that cell type-specific enrichment of genes mapped to GWAS loci of complex diseases and traits can help identify cell types of action for diseases in relevant tissues^{38,39}. 93

In this study, we have combined expression quantitative trait loci (eQTLs) and splicing QTLs
 (sQTLs) in 49 (non-ocular) tissues from the Genotype-Tissue Expression (GTEx) Project²⁶, retinal
 eQTLs^{31,32}, retinal Hi-C data⁴⁰, and single-cell expression from glaucoma-relevant eye tissues^{33,36,37}
 with POAG and IOP genetic associations to identify regulatory mechanisms, genes, pathways, and
 cell types that may play an important role in POAG etiology.

99 Results

100 An overview of the analytical steps and approaches taken are described in Fig. 1 and 101 Supplementary Note.

102

103 POAG and IOP associations enriched among eQTLs and sQTLs. To assess the relevance of 104 eQTLs and sQTLs to POAG risk and IOP variation, we tested whether cis-eQTLs and cis-sQTLs 105 (e/sQTLs) from 49 GTEx (v8) tissues²⁶ and peripheral retina *cis*-eQTLs^{27,28} were enriched for POAG or IOP associations (GWAS P<0.05) using QTLEnrich^{24,26} that adjusts for confounding factors and 106 107 tissue sample size (Methods and Fig. 1a). We found significant enrichment of multiple POAG and 108 IOP associations (both genome-wide significant and subthreshold) among eQTLs and sQTLs in most of the 49 GTEx tissues and in retina (Bonferroni-corrected P<5x10⁻⁴) (Fig. 2a, b and 109 110 Supplementary Tables 1-3). Many of the top enriched GTEx tissues contain cell types that may be pathogenic to glaucoma (Supplementary Note). The relative contribution of sQTLs to POAG and 111 112 IOP, as measured by adjusted fold-enrichment and estimated true positive rate, was larger than 113 the relative contribution of eQTLs to these traits (One-sided Wilcoxon rank sum test P<1.5x10⁻¹¹ and P<0.03, respectively: Supplementary Fig. 1a-c, and Supplementary Tables 1-3), as observed 114 with other complex traits²⁶. The absolute number of eQTLs proposed to contribute to POAG and 115 116 IOP (average 258 to 606 per tissue) was 2-fold larger than that of sQTLs (average 124 to 320 per tissue), likely due to the larger discovery rate of eQTLs compared to sQTLs²⁶ (Supplementary Fig. 117 118 1a-c and Supplementary Table 1). The target genes of eQTLs or sQTLs with top-ranked POAG or 119 IOP GWAS p-values (P<0.05) were enriched in metabolic and cellular processes (Methods; 120 Supplementary Tables 4-5; Supplementary Note).

121

122 Colocalization analysis of POAG and IOP GWAS loci with cis-e/sQTLs. Given the widespread 123 e/sQTL enrichment of POAG and IOP associations, we used the e/sQTLs in all 49 GTEx tissues 124 and retina eQTLs to propose putative causal genes that may underlie genome-wide significant loci for these traits. We applied two colocalization methods, eCAVIAR⁴¹ and *enloc*⁴², to 127 POAG loci 125 from a large cross-ancestry GWAS meta-analysis⁸, 68 POAG loci from a European (EUR) subset 126 meta-analysis⁸ (POAG EUR), and 133 IOP loci from a primarily European GWAS meta-analysis⁹ 127 128 (IOP) (variant list in Supplementary Table 6; Methods and Fig. 1a), and any e/sQTLs that 129 overlapped each GWAS locus LD interval (Methods). The results are presented per trait and 130 colocalization method in Supplementary Tables 7-12 and summarized in Supplementary Table 13. We defined a "comprehensive set" of putative causal genes and regulatory mechanisms for POAG 131 132 and IOP as those e/sGenes that were significant with at least one of the colocalization methods 133 (Colocalization posterior probability (CLPP) > 0.01 for eCAVIAR, and regional colocalization 134 probability (RCP) > 0.1 for enloc (see Methods); Supplementary Table 13), filtering out potential 135 false positives (See Methods and examples in Supplementary Fig. 3). The largest number of 136 colocalizing e/sGenes was found in tibial nerve, adipose, skin, artery, and fibroblasts, among other

137 tissues, many of which contain cell types relevant to the pathogenicity of glaucoma (Supplementary 138 Fig. 4). Eighteen retina eQTLs colocalized with 13 POAG and/or IOP loci (Column AH in 139 Supplementary Table 13). The number of significantly colocalizing e/sGenes per tissue significantly correlated with tissue sample size (Pearson's $R^2=0.72$, $P=1x10^{-14}$, Supplementary Fig. 4) that is 140 also associated with the number of detected e/sQTLs per tissue²⁶. This suggests that e/sQTL 141 142 discovery power is a driving factor in tissue identity of the colocalizing e/sQTLs. We therefore 143 primarily considered the causal genes proposed by the colocalization analysis and not the 144 associated tissues, in downstream analyses.

145 We found that 58% of all GWAS loci tested significantly colocalized with at least one eQTL and/or sQTL based on eCAVIAR and/or enloc: 60% (76) of 127 cross-ancestry POAG GWAS loci, 146 147 53% (36) of 68 European POAG loci and 59% (79) of 133 IOP loci (Fig. 2c and Supplementary 148 Table 14). About 55% and 29% of GWAS loci colocalized with ≥ 1 eQTL and ≥ 1 sQTL, respectively. 149 For 21% of the POAG and IOP GWAS loci (69 loci total), significant colocalization was found for 150 the same e/sGene with eCAVIAR and enloc ('high confidence set' listed in Table 1 and 151 Supplementary Table 15). The GWAS-e/sQTL colocalization analysis significantly reduced the 152 number of putative causal genes per GWAS locus for POAG and IOP from an average of 22.8 ± 153 1.8 genes tested per LD interval (range: 3-166, median=15) to an average of 3.5 ± 0.4 genes per 154 locus (range: 1-36, median of 1 or 2 genes per locus per trait; Fig. 2d,e and Supplementary Table 155 16). eQTLs and sQTLs nominated an average of 3 and 2 causal genes per locus, respectively, with 156 partial overlap of target genes between the colocalizing eQTLs and sQTLs (Fig. 2e and 157 Supplementary Table 16). 60-72% of the colocalizing e/sGenes per trait were protein-coding and 158 18-20% were noncoding RNA genes, half of which were lincRNAs and half antisense genes (Fig. 159 2f, Supplementary Tables 17-18, and Supplementary Note). A single causal gene was proposed for 80 (42%) of the POAG and IOP loci with significantly colocalizing e/sQTLs (Supplementary 160 161 Tables 19-20), 49 (61%) of which are the nearest gene to the lead GWAS variant. In 30.3% (23/76), 162 16.7% (6/36) and 31.7% (25/79) of the POAG cross-ancestry, POAG EUR and IOP GWAS loci, 163 respectively, with significant colocalization results, the colocalizing e/sGenes were not the nearest 164 gene to the lead GWAS variant. In total, 228, 118, and 279 genes, including previously suggested and novel ones, are candidate causal genes for POAG cross-ancestry risk, POAG EUR risk, and 165 166 IOP variation, respectively (Supplementary Table 21), with a total of 459 genes proposed from the 167 combined datasets.

168

Colocalizing e/sGenes of top POAG and IOP GWAS loci and direction of regulatory effect
 on disease risk. In addition to prioritizing causal genes and regulatory mechanisms that may

171 contribute to POAG and IOP, colocalizing e/sQTLs propose the direction of effect of altered gene 172 expression or splicing on disease risk or trait variation (examples for top POAG and IOP GWAS 173 signals in Fig. 3 and Supplementary Fig. 5). For example, an eQTL and sQTL acting on TMCO1 and an eQTL acting on TMCO1's antisense, RP11-466F5.8, in the opposite direction, colocalized 174 175 with the second strongest association with POAG (rs2790053, odds ratio (OR)=1.35; CLPP=0.92-176 1) and the top IOP association (rs116089225, beta = -0.744; CLPP=0.87-1) (Fig. 4a-e and 177 Supplementary Fig. 6). Decreased expression of TMCO1 and increased expression of RP11-466F5.8 are proposed to lead to increased IOP levels and increased POAG risk (Fig. 4, 178 179 Supplementary Fig. 6, and Supplementary Table 13). Furthermore, an alternative splice donor site 180 in exon 4, the first exon in the TMCO1 mRNA in GTEx Cells Cultured fibroblasts, leads to a longer 181 exon 4 (Fig. 4f,g) that is associated with decreased POAG risk (Supplementary Tables 7 and 13). 182 TMCO1 is expressed in different cell types in the anterior and posterior parts of the eye, including 183 lymphatic and fibroblast cells in the conventional and unconventional outflow pathways, vascular 184 and immune cells in the anterior and posterior segments, and macroglial cells in the retina 185 (Supplementary Figure 7). Other examples include ANGPT1 and ANGPT2, involved in vascular 186 biology, whose increased expression is proposed to reduce IOP levels (Supplementary Fig. 8 and 187 Supplementary Table 13) that is consistent with the effect observed on IOP in Angpt1-knockout 188 mice⁴³.

189

190 Colocalizing genes for shared and distinct POAG and IOP loci. Of 50 overlapping POAG and 191 IOP GWAS loci, 39 (78%) of the loci had at least one significant colocalization result for both traits, 192 and in all cases at least one common gene was implicated (Supplementary Table 13 and Table 1). 193 In most of the cases (95%), the relative direction of effect of the colocalizing e/sQTLs on IOP was consistent with IOP's effect on POAG risk, proposing IOP-dependent mechanisms for POAG risk. 194 195 For example, decreased GAS7 expression or increased ABO expression were associated with both 196 increased IOP levels and increased POAG risk (Supplementary Tables 7-13 and Supplementary 197 Figs. 9-10). e/sGenes that colocalize with POAG loci not associated with IOP (48 loci; Column N 198 in Supplementary Table 13) may suggest IOP-independent mechanisms.

To prioritize regulatory variants and genes that may affect POAG independent of IOP, we integrated retina Hi-C loops and/or epigenetically derived *cis*-regulatory elements (CREs) and super-enhancers (SEs) (Supplemental Data 4 in Marchal *et al.*⁴⁰) with the POAG-only loci (Methods). In 17 of the loci, \geq 1 colocalizing e/sQTLs was supported as a potential causal mechanism by retina Hi-C loops (6 loci), CREs (16 loci) and/or SEs (5 loci) (Supplementary Table 22). This includes the strongest normal tension glaucoma (NTG) association (9p21)^{8,44} in the POAG

205 cross-ancestry (rs944801 OR=1.26) and POAG EUR (rs6475604 OR=1.3) GWAS meta-analyses 206 that colocalized with a CDKN2A eQTL in brain cortex, CDKN2B-AS1 and RP11-149I2.4 sQTLs in 207 pituitary, and CDKN2B eQTL in skeletal muscle (Supplementary Table 13). The POAG risk variants 208 and colocalizing e/sQTLs in this locus overlapped retinal CREs (Fig. 5a). These results imply that 209 increased expression of CDKN2A, decreased expression of CDKN2B, and exon skipping in 210 CDKN2B-AS1 may increase POAG risk (Fig. 3, Supplementary Figs. 5a and 11). Other examples, 211 involving a retina SLC2A12 eQTL overlapping a retinal CRE, and e/sQTLs acting on RERE and its 212 antisense, RERE-AS1, that are physically linked via retina chromatin loops to the RERE 213 transcription start site (TSS), are shown in Fig. 5b and c (see also Supplementary Table 22). 214 Notably, RERE expression is enriched in oligodendrocytes in the optic nerve head and optic nerve 215 (False discovery rate (FDR)=0.07) and in retinal pigment epithelium (RPE) and S-cones in the 216 macula (FDR=0.06), as shown below (Supplementary Table 38; Supplementary Fig. 18f, g).

217

218 Colocalizing genes in population-specific and cross-ancestry POAG loci. For all 59 POAG 219 EUR loci also found in the POAG cross-ancestry meta-analysis, at least one common colocalizing 220 e/sGene was found for both the EUR and cross-ancestry GWAS (Supplementary Table 13). One 221 such example is *EFEMP1*, in which rare mutations have been associated with a Mendelian form of 222 glaucoma⁴⁵. Colocalization analysis suggests that skipping of exons 6 and 7 in *EFEMP1* may be protective for POAG (Supplementary Fig. 12). Of the 9 loci found only in the POAG EUR GWAS, 223 224 two loci colocalized with eQTLs acting on several genes each, including genes involved in the 225 extracellular matrix (EMID1) and vascular endothelial growth (ANGPTL2), respectively, both of 226 which also colocalized with IOP (Supplementary Table 23). In addition, three associations in the 227 POAG cross-ancestry meta-analysis demonstrated significant allelic heterogeneity among the three populations (European, East Asian, and African American)⁸. e/sQTL colocalized with two of 228 229 these loci. One is the 9p21 locus rs944801 with CDKN2A/B described above, which was significant 230 in the European and Asian populations, but not the African population (P heterogeneity=1.5 x 10⁻ 231 ⁸) in which it is in lower frequency (AFR MAF=0.073, EUR MAF=0.42, EAS MAF=0.11 in gnomAD 232 (URLs)). The other is a European-specific locus with the largest POAG odds ratio (rs74315329, 233 OR=5.47). This variant is a nonsense mutation (p.Gln368Ter) in MYOC, known to cause juvenileonset and adult-onset open-angle glaucoma with dominant inheritance⁴⁶. This variant is 10-fold 234 235 more common in the European population compared to the African population and is not found in 236 the East Asian population (gnomAD; URLs). Of all the e/sQTL gene-tissue pairs that overlapped 237 this locus targeting 24 genes, we identified an sQTL acting on PIGC, phosphatidylinositol glycan 238 anchor biosynthesis class C, that significantly colocalized with the POAG cross-ancestry locus

239 (spleen CLPP=0.12, and arterial tissues RCP=0.26-0.34; Supplementary Table 13 and 240 Supplementary Fig. 13). Conditioning on the nonsense variant in MYOC that is likely the primary 241 causal variant in the locus, we found that a secondary haplotype colocalized with the PIGC sQTL 242 (Supplementary Tables 24-28; more details in Supplementary Note). These results suggest that 243 decreased exon 2 skipping in PIGC or increased PIGC expression may lead to increased POAG 244 risk (Supplementary Fig. 13). PIGC is among 10 colocalizing POAG genes enriched in 245 oligodendrocytes in the optic nerve head and optic nerve (See below; FDR=0.07, Supplementary 246 Table 38; Supplementary Fig. 18f, g).

247

248 Mendelian randomization (MR) of colocalizing e/sQTLs. To provide additional support for a 249 causal relationship between e/sQTLs and POAG and/or IOP, we applied two-sample MR to all the 250 significantly colocalizing e/sQTL and GWAS locus pairs based on eCAVIAR and/or enloc 251 (Methods). We found evidence for a causal relationship (FDR < 0.05) for 348 (75%) genes that 252 were robust to the influence of horizontal pleiotropy, where pleiotropy-robust sensitivity could be 253 performed (Supplementary Table 29). A high-confidence list of putative POAG and/or IOP causal 254 genes based on colocalization analysis and MR is provided in Table 1. We found 239 e/sGenes to 255 have significant MR associations with both POAG and IOP, including TMCO1, GAS7, and LMX1B, 256 which colocalized with the largest association signals for both POAG and IOP GWAS loci 257 (Supplementary Figs. 5, 6, 9), and DGKG and NPC2, whose retina eQTLs colocalized with POAG 258 and IOP. Sixty-eight genes had significant MR associations with IOP but not POAG, such as HLA-259 B and SLC7A6, and 41 genes had significant MR associations with POAG but not IOP, such as 260 CDKN2B-AS1, RERE, and YAP1, proposing high-confidence IOP-independent mechanisms 261 (Supplementary Table 29 and Fig. 5). Since the MR analysis could not be applied to the larger, 262 better-powered POAG cross-ancestry GWAS, as it requires a similar population background 263 between the e/sQTL and GWAS studies (European in our case), our downstream analyses were 264 applied to the more inclusive list of proposed causal genes based on the colocalization analysis 265 (Supplementary Table 13).

266

Enrichment of POAG and IOP colocalizing e/sGenes in biological processes. To gain biological insight into ways the implicated genes might contribute to glaucoma pathogenesis, we next tested whether the target genes of all the colocalizing e/sQTLs with POAG cross-ancestry, POAG EUR, or IOP GWAS loci were enriched in specific biological pathways, gene ontologies, or mouse phenotype ontologies, using *GeneEnrich* (Methods and Fig. 1c). Genes that colocalized with POAG cross-ancestry loci were significantly enriched in elastic fiber formation (Empirical P-

273 value (P)<1x10⁻⁵, FDR<0.001) and extracellular matrix organization (P=3x10⁻⁵, FDR=0.012), and 274 nominally enriched (P<0.05) in the transforming growth factor beta (TGF) receptor signaling 275 pathway ($P=3x10^{-4}$) and abnormal eye morphology ($P=2.6x10^{-3}$), amongst others (Supplementary 276 Table 30 and Supplementary Fig. 14a,b). Genes that colocalized with POAG EUR loci were nominally enriched ($P < 4x10^{-3}$) in cellular senescence and cell cycle processes (e.g., Cyclin D-277 278 associated events in G1), lipid-related processes, such as apolipoprotein binding and decreased 279 circulating high-density lipoprotein cholesterol level, and retina or neuronal related processes, 280 including abnormal retina morphology, abnormal sensory neuron innervation pattern, and negative 281 regulation of axon extension involved in axon guidance (Supplementary Table 31 and 282 Supplementary Fig. 14c,d).

283 For the IOP genes, significant enrichment (P=2x10⁻⁵, FDR=0.025) was found in 284 transcriptional regulation by VENTX, a gene that encodes a homeodomain-containing transcription 285 factor (Supplementary Table 32 and Supplementary fig. 14e). VENTX and its IOP-colocalizing 286 target genes driving the gene set enrichment signal (ANAPC1, ANAPC7, AGO4, MOV10, TCF7L2) 287 were most highly expressed in immune cell types, lymphocytes and macrophages, in the single cell 288 anterior segment and optic nerve head described below (Supplementary Fig. 14f). The IOP genes 289 were also significantly enriched (FDR<0.15) in blood vessel morphogenesis and vasculature 290 development, regulation of cytoskeletal organization, negative regulation of cellular component 291 organization, and adherens junction (Supplementary Table 32 and Supplementary Fig. 14e). Since 292 colocalization with multiple e/sQTLs was found for two GWAS loci in the HLA region on 293 chromosome 6 associated with POAG and IOP (29 and 35 e/sGenes, respectively), likely due to 294 high LD in the HLA region, we removed this region from the gene set enrichment analysis above 295 to avoid inflating the results due to a single locus. When kept in, the endosomal vacuolar pathway, 296 interferon gamma signaling, antigen presentation folding assembly and peptide loading of class I 297 MHC, negative regulation of natural killer cell-mediated immunity, and cell aging were significantly 298 enriched (FDR<0.1) for POAG genes (Supplementary Table 33), in addition to the gene sets above. 299 The colocalizing POAG and IOP genes driving the gene set enrichment signals are listed in 300 Supplementary Tables 30-33.

301

Identifying pathogenic cell types for POAG and related ocular traits. To further relate the implicated genes to pathogenic mechanisms and cell types, we next tested whether the expression of POAG or IOP colocalizing e/sGenes was enriched in specific cell types in key eye tissues implicated in the pathophysiology of POAG. We first applied ECLIPSER^{38,39} (Methods and Fig. 1d) to 228, 118, and 279 e/sGenes that colocalized with POAG cross-ancestry, POAG EUR and IOP

307 GWAS loci, respectively (Supplementary Tables 13 and 34), and to cell type-specific expression 308 from single nucleus (sn) RNA-seq of 13 tissues dissected from non-diseased human eyes: central 309 cornea, corneoscleral wedge (CSW), trabecular meshwork (TM) including Schlemm's canal, iris, 310 ciliary body (CB), lens³⁶ (all from anterior segment), peripheral and macular retina^{33,36}, the optic 311 nerve head (ONH), optic nerve (ON), peripapillary sclera (PPS), peripheral sclera, and choroid³⁷ 312 (all from posterior segment) (Methods and Supplementary Tables 35-37). The cell type enrichment 313 results are summarized in Supplementary Table 38.

In the anterior segment, we found significant enrichment (tissue-wide FDR<0.1) for POAG 314 EUR loci in fibroblasts derived from the ciliary muscle (present in CB, CSW and TM³⁶), annotated 315 as ciliary fibroblasts in van Zyl et al.³⁶, followed by fibroblasts derived from the iris root (present 316 317 within the iris³⁶), annotated as iris fibroblasts (Supplementary Table 38 and Fig. 6a,b). The ciliary 318 muscle and iris are key tissues involved in the unconventional outflow pathway. These fibroblasts 319 were also detected histologically within the TM where all three tissues meet and interweave at the iridocorneal angle³⁶, implicating the conventional aqueous outflow pathway as well. Fig. 6c shows 320 321 the e/sGenes driving the POAG EUR enrichment signal in ciliary fibroblasts. The POAG EUR genes 322 were also modestly enriched in fibroblasts derived predominantly from the TM tissue (annotated as TM fibroblasts³⁶) (P=0.014, FDR=0.18). For POAG cross-ancestry and IOP loci, we found 323 324 supportive enrichment (P<0.05, FDR<0.23) in outflow pathway and cornea fibroblasts, vascular endothelium cells (cluster 2 derived from TM, CSW and CB tissues³⁶), and lens epithelium, as 325 326 detailed in Fig. 6a,d,e and Supplementary Table 38. Genes that colocalized with IOP loci were also significantly enriched (FDR<0.1) in pericytes (cluster 2 that localizes to the CSW³⁶), and nominally 327 328 enriched in lymphatic endothelium and Schlemm's canal, whose dysfunction can lead to elevated 329 IOP⁴⁷ (Fig. 6e and Supplementary Table 38).

Clustering of the top-ranked anterior segment cell types (P<0.05) for POAG and IOP, 330 331 separately, based on the overlap of genes driving the cell type enrichment, suggests three cell 332 classes affecting POAG - fibroblasts, vascular endothelium, and lens epithelium; and three cell 333 classes for IOP - fibroblasts, pericytes, and lymphatic endothelial cells (Fig. 6f, g). Between 45-334 78% of the genes driving the POAG enrichment signals in the outflow fibroblast cell types are 335 common between the different fibroblasts (Fig. 6f), suggesting both shared and distinct genes 336 acting in the conventional and unconventional outflow pathways. The IOP genes driving the 337 enrichment signal in pericytes (Fig. 6h,i) were largely distinct from those enriched in vascular and 338 fibroblast cell types (overlap 7-33%; Fig. 6q), and were enriched in vasculature development 339 (P=3x10⁻⁵, FDR=0.075; Supplementary Table 40). On the other hand, the IOP genes driving the 340 enrichment in TM fibroblasts (Supplementary Fig. 15c,d) were highly shared with the IOP genes

341 enriched in ciliary and iris fibroblasts (overlap 64-88%; Fig. 6g). Notably, the enrichment of IOP 342 genes in pericytes was specific to IOP (asterisks in Fig. 6h). When ECLIPSER was applied to genes 343 that colocalized with IOP loci not associated with POAG, only the enrichment in pericytes remained 344 (P=0.007) (Supplementary Table 41 and Supplementary Fig. 15e). Genes mapped to shared IOP 345 and POAG loci were significantly enriched in ciliary and TM fibroblasts (FDR<0.01) and lymphatic 346 or vascular endothelial cells (FDR=0.026). No enrichment was found for POAG-only loci in the 347 anterior segment cell types, supporting IOP-dependent mechanisms in the anterior segment for 348 POAG risk, as expected (Supplementary Table 41).

349 We next tested for enrichment of POAG and IOP colocalizing e/sGenes in retina snRNA-350 seg data (Methods). We found significant enrichment of POAG cross-ancestry genes in astrocytes 351 and Müller glia cells (FDR<0.04; Supplementary Table 38, Fig. 7a and Supplementary Fig. 16a), 352 which replicated (FDR<0.06) in a separate snRNA-seg study of the macula (Methods: 353 Supplementary Table 38 and Supplementary Fig. 16g). Consistent results were found for POAG 354 EUR genes (Supplementary Fig. 16b). A guarter (YAP1, LPP, TRIB2) of the 12 POAG cross-355 ancestry genes driving the astrocyte enrichment were common with Müller glia cells 356 (Supplementary Fig. 16d, e), suggesting both shared and distinct processes between the two cell 357 types. IOP genes were only nominally enriched in astrocytes (P=0.032; Supplementary Fig. 16c). 358 By testing POAG- or IOP-only loci and shared loci, the POAG enrichment in retinal astrocytes and 359 Müller glia cells appears to be independent of IOP (Supplementary Table 41 and Supplementary 360 Fig. 17; more details in Supplementary Note). The POAG cross-ancestry genes were also enriched 361 in RPE cells and S-cones in the macula (FDR=0.06). Of note, no significant enrichment was 362 observed in RGCs (Fig. 7a), though some POAG colocalizing e/sGenes are expressed in RGCs 363 (Supplementary Fig. 20).

364 Finally, we tested for cell type-specific enrichment in the optic nerve head (ONH), optic 365 nerve (ON) and adjacent posterior tissues (Methods; Supplementary Table 37). The strongest 366 enrichment (FDR<0.01) of POAG cross-ancestry genes was found in fibroblasts primarily in the 367 peripapillary sclera (PPS) that encompasses the ONH, followed by fibroblasts most abundant in 368 the choroid, astrocytes that reside in the ONH and ON, Schwann cells in the choroid and PPS, 369 oligodendrocyte precursor cells (OPCs) and oligodendrocytes in the ON and ONH (Supplementary 370 Fig. 18f,g), and vascular endothelium cells primarily in the choroid (FDR<0.09; Fig 7b,c, 371 Supplementary Table 38 and Supplementary Fig. 18a,d). POAG EUR genes showed similar 372 enrichment patterns (Fig. 7b, Supplementary Fig. 18b and Supplementary Table 38). About half 373 the genes driving the enrichment in astrocytes in ONH (Fig. 7d, e) and retina samples from separate 374 donors were common (e.g., DGKG, PLCE1, LPP, GAS7, YAP1, and COL11A1; Supplementary

Table 38). *DGKG*, diacylglycerol kinase gamma, whose retina-specific eQTL colocalized (CLPP=0.96) with POAG cross-ancestry association (Fig. 7f) displayed the strongest cell type specificity in ONH (Fig. 7d) and retinal astrocytes (Supplementary Fig. 16d).

378 IOP genes were most significantly enriched in vascular endothelial cells and fibroblasts 379 primarily residing in the choroid, but also in the ONH and PPS (FDR<0.014), followed by Schwann cells in the choroid and PPS, vascular smooth muscle cells (19-ACTA2; Supplementary Fig. 18h,i) 380 381 in the PPS and sclera, pericytes (26-ACTA2) in the ONH, PPS and choroid, and OPCs in the ON 382 (FDR<0.06; Fig. 7b, Supplementary Table 38, and Supplementary Fig. 18a,c,e). The IOP genes 383 driving enrichment in vascular endothelial cells in the ONH, choroid and posterior tissues were 384 enriched in vasculature development and anchoring junction gene ontologies (FDR<0.06), and IOP 385 genes enriched in pericytes in the ONH, choroid and PPS were enriched in TIE2 signaling 386 (FDR=0.02), response to carbohydrate adhesion (FDR=0.13), and negative regulation of cell 387 adhesion (FDR=0.13) (Supplementary Table 40). Notably, the enrichment in oligodendrocytes and 388 OPCs was specific to POAG-only loci, and enrichment in vascular endothelium and mural cells was 389 specific to IOP-only loci (Supplementary Table 41 and Supplementary Fig. 19).

390 The cell type expression profiles of all POAG cross-ancestry, POAG EUR and IOP 391 colocalizing e/sGenes is shown in Supplementary Fig. 20, and a summary of the cell types and 392 pathways in which each of the POAG and IOP colocalizing e/sGenes are enriched is presented in 393 Supplementary Tables 42-44. Applying ECLIPSER to various negative control traits suggests that 394 the cell type enrichment results are specific to glaucoma and not due to unaccounted confounding 395 factors (Supplementary Tables 45-46, Fig. 6a, and Supplementary Fig. 21; Supplementary Note). 396 Furthermore, the ECLIPSER cell type enrichment significance did not correlate with cell count per 397 cell type in the single-nucleus datasets (Pearson's $R^2 < 0.2$, P>0.12; Supplementary Table 47).

To increase confidence in the POAG and IOP cell type enrichment results, we applied two 398 399 additional methods that identify cell types associated with complex traits, through regression 400 analysis of genome-wide associations beyond known GWAS loci: stratified LD score regression 401 (S-LDSC) and MAGMA (Fig. 1e; Methods). The primary enriched cell types for POAG and IOP 402 found with ECLIPSER, including ciliary and TM fibroblasts, ONH fibroblasts, and retinal macroglial 403 cells, were significant with S-LDSC (Supplementary Table 48; Supplementary Fig. 22) and more 404 restrictively with MAGMA (Supplementary Table 49; Supplementary Fig. 22); additional enrichment 405 was found in vascular types. Enrichment of POAG loci in ONH and ON oligodendrocytes was only 406 found with ECLIPSER suggesting that the enrichment is primarily driven by genes with strong 407 genetic effects. The cell type enrichment significance of ECLIPSER was reasonably correlated with 408 that of S-LDSC and MAGMA (Average Pearson's r=0.53, range: 0.18-0.86; Supplementary Table

409 50). We further used conditional analysis implemented in MAGMA to test whether the different cell 410 type enrichment signals for POAG or IOP were independent of each other in each tissue 411 (Supplementary Table 51). In the anterior segment, the enrichment of POAG associations in ciliary 412 fibroblasts was independent of TM fibroblasts, but not vice versa (Conditional P=0.04). In retina, 413 POAG associations were significantly enriched in astrocytes (P<6E-8) and Müller glia cells 414 (P<0.002), but only astrocytes remained significant after conditional analysis (Conditional P<4E-6). 415 suggesting that astrocytes may play a more important role in glaucoma pathogenicity than Müller 416 Glia cells. In the ONH, the POAG and IOP enrichment in fibroblasts, astrocytes, vascular 417 endothelium, and mural cells were all independent of each other (Supplementary Table 51).

418 Finally, to augment the POAG and IOP enrichment analysis, we tested for cell type 419 enrichment of genes mapped to GWAS loci of additional glaucoma associated traits (listed in 420 Supplementary Table 34), including vertical-cup-to-disc ratio (VCDR), cornea hysteresis, and 421 central cornea thickness (Methods) in all ocular tissue regions (Supplementary Table 38, Fig. 6a 422 and Fig. 7a, b). In the anterior segment, genes mapped to central corneal thickness and corneal 423 hysteresis were most significantly enriched in corneal fibroblasts (FDR<0.007; Fig. 6a and 424 Supplementary Fig. 23a, b), highlighting the specificity of the POAG and IOP gene enrichment in 425 the outflow pathway fibroblasts. The VCDR GWAS loci from a well-powered GWAS that used deep 426 learning (ML) to score the characteristics of fundus images from 65,680 European individuals¹² 427 showed significant enrichment in the TM fibroblasts from the conventional outflow pathway 428 (FDR=0.02; Fig. 6a and Supplementary Fig. 23c). TM fibroblasts were also the top nominally enriched cell type for a smaller VCDR GWAS, where 23,899 fundus images were manually scored 429 430 by ophthalmologists¹³ (P=0.0076, FDR=0.3; Fig. 6a and Supplementary Fig. 23d). In the retina, the 431 ML-based VCDR loci displayed significant enrichment in GABAergic amacrine cells, cone photoreceptors and Müller glia cells (FDR<0.085; Fig. 7a and Supplementary Fig. 23e) and nominal 432 433 enrichment in astrocytes. In the ONH, the ML-based VCDR genes were nominally enriched in 434 fibroblasts in the PPS, vascular endothelium primarily in the choroid, and astrocytes in the ONH 435 and ON, similarly to POAG loci (Fig. 7b and Supplementary Fig. 23g, h; Supplementary Table 38).

In summary, our cell type enrichment analysis has revealed roles for both known and less well-studied cell types in POAG pathogenicity, such as fibroblasts in the unconventional and conventional outflow pathways, astrocytes in retina and ONH, OPCs in the ON and ONH, and Schwann cells and fibroblasts in the PPS and choroid. It also suggests known and new causal genes for POAG and related eye traits that may be affecting glaucoma susceptibility through specific cell types in the anterior and posterior parts of the eye in IOP-dependent and independent manners (Supplementary Tables 38 and 41).

443 Discussion

444

We report results of a systematic investigation of the underlying causal mechanisms, genes 445 and cell types of over 130 cross-ancestry or European loci associated with POAG^{8,9} and over 110 446 loci associated with its major risk factor, elevated IOP9. Our analysis integrated a variety of 447 datasets, including expression and splicing QTLs from 49 GTEx tissues²⁶ and from retina^{26,27}, 448 genome topology data from retina⁴⁰, single-nucleus expression data from a whole-eye cell atlas 449 that includes key structures of both the anterior³⁶ and posterior segments^{33,37}, and the largest to 450 date GWAS meta-analyses for these traits^{8,9}. Our finding that eQTLs and sQTLs in GTEx tissues 451 452 and retina are enriched for hundreds of known and more modest POAG and IOP associations, 453 suggests a primary role for transcriptional regulation in POAG susceptibility, as observed for other diseases^{24–27}, and implies that GTEx tissues can be used to uncover causal mechanisms for 454 455 glaucoma. The GTEx e/sQTLs likely capture shared genetic regulation with the actual pathogenic 456 tissues for glaucoma, such as fibroblasts and vascular endothelial cells, as well as shared regulation across cell types and tissues²⁶. 457

Using two QTL/GWAS colocalization methods^{41,42}, we prioritized putative causal genes for 458 ~60% of the POAG and IOP GWAS loci. A similar fraction of GWAS loci with significant 459 460 colocalization results has been found for other complex diseases and traits^{26,48}. For a guarter (80) of the POAG and IOP loci, a single gene was proposed, ten of which are noncoding genes (lincRNA 461 462 and antisense), suggesting that transcriptional and post-transcriptional gene regulation contribute 463 to glaucoma susceptibility. We provided additional support for three guarters of the colocalizing e/sGenes using Mendelian randomization^{49,50,51}, which tests for horizontal pleiotropy, not accounted 464 for by Bayesian colocalization analysis^{52,53}. For about one third of the GWAS loci, none of the 465 proposed causal gene/s were the nearest gene to the lead GWAS variant, similar to that observed 466 for other complex traits^{24,48,54}. These results emphasize the value of using e/sQTLs or other 467 functional assays that link regulatory regions to distal target genes^{24,55–57} to prioritize causal genes 468 469 underlying common variant associations.

Integrating e/sQTLs with POAG and IOP GWAS loci proposed both previously suggested⁸ and new biological processes for these traits. The POAG colocalizing genes, which included several known mendelian, early-onset glaucoma genes (*EFEMP1*^{45,58} and *LTBP2*⁵⁹), were most strongly enriched in extracellular matrix organization and elastic fiber formation, as previously reported⁸, followed by TGF receptor signaling pathway. Structural changes of the extracellular matrix induced by TGF-beta2 in both the trabecular meshwork in the outflow pathway and the optic nerve head have been associated with POAG⁶⁰, and have been suggested to cause impairment of

477 optic nerve axonal transport and neurotrophic supply that could influence RGC degeneration⁶⁰. 478 Regulation by the homeodomain transcription factor, VENTX, was the most significantly enriched 479 gene set for IOP genes, which has not yet been associated with glaucoma. VENTX is proposed to play important roles during embryonic patterning (by homology), including in neural crest 480 development⁶¹, as well as hematopoiesis, leukemogenesis, cellular senescence and macrophage 481 differentiation⁶². Its strongest expression in our single cell data was in lymphocytes in the anterior 482 483 segment, and macrophages in the optic nerve head, proposing a novel link between immune-484 related processes and IOP levels. Reduced circulating endothelial progenitor cells has been reported in POAG patients⁶³, which could explain impaired flow-mediated vasodilation in POAG⁶⁴. 485 Additional processes suggested to affect IOP regulation, aside from previously suggested⁹ vascular 486 487 development, are regulation of cytoskeleton organization, and adherens junction, a cell-cell junction 488 whose cytoplasmic face is linked to the actin cytoskeleton, and that allows cells to respond to 489 biomechanical forces and structural changes in the tissue microenvironment⁶⁵. Inhibition of 490 adherens junction regulation in trabecular meshwork has been shown to modestly influence IOP levels in rabbits⁶⁶. We also found modest enrichment of POAG genes in neuronal-related 491 492 processes, including genes affecting retinal morphology, sensory neuron innervation pattern, and 493 regulation of axon guidance. These genes may represent IOP-independent mechanisms, which 494 will need to be corroborated in future GWAS with larger numbers of normal tension glaucoma 495 cases.

496 In addition to prioritizing causal genes for POAG and IOP, e/sQTLs suggest the direction of 497 effect of gene expression changes or alternative splicing on disease risk that could inform drug 498 design. In this study, we provide various hypotheses of putative causal genes and regulatory 499 mechanisms that may affect POAG susceptibility in an IOP-dependent or independent manner, for 500 experimental follow up. For example, an increase in expression or alternative splicing of TMCO1, 501 a gene that regulates the balance of calcium ions inside the endoplasmic reticulum, or a decrease 502 in expression of LMX1B, LIM homeobox transcription factor 1 beta, that is essential for several 503 developmental processes including the anterior segment of the eye⁶⁷, were proposed to reduce 504 POAG risk and IOP levels. The lead IOP GWAS variant (rs116089225) in TMCO1 that colocalized 505 with TMCO1 e/sQTLs has been recently associated with variable number tandem repeat (VNTR) length in the UK biobank study⁶⁸. However, the VNTR did not display allelic series association with 506 TMCO1 expression levels in GTEx⁶⁸, suggesting that the GWAS variant might be tagging more 507 508 than one causal mechanism. As for IOP-independent mechanisms, an sQTL acting on CDKN2B-509 AS1, which leads to skipping of exons 2 and 3 that overlap the CDKN2B gene on the opposite 510 strand, is proposed as a potential mechanism of action for the protective signal found in this gene⁶⁹.

511 Skipping of these exons might render the CDKN2B antisense less efficient in forming a complex 512 with the CDKN2B RNA. Retinal Hi-C and epigenetic data further support potential roles for e/sQTL 513 effects on POAG in the retina, such as increased expression of RERE (arginine-glutamic acid 514 dipeptide repeats) proposed to increase POAG risk. Of note, RERE has also been associated with VCDR¹³. Overexpression of the *RERE* protein that co-localizes with a nuclear transcription factor 515 516 triggers apoptosis, and its deficiency in mice causes retinal and optic nerve atrophy⁷⁰. This study also suggested a potential secondary causal gene, PIGC for the strongest POAG association, a 517 518 nonsense mutation in MYOC, which will need to be replicated in a larger independent POAG 519 GWAS. The MYOC mutation causes aggregation of misfolded myocilin proteins in the trabecular meshwork, which may lead to elevated IOP levels⁷¹. Conversely, the enrichment of *PIGC* (that 520 521 encodes an endoplasmic reticulum-associated protein) expression, along with other POAG-522 colocalizing genes, in oligodendrocytes in the optic nerve head (ONH), suggests a secondary 523 causal role for this locus in RGC support, in the posterior part of the eye.

524 There are several reasons why we may not have found colocalizing e/sQTLs for 40% of the 525 loci. First, some of the causal genes or regulatory effects may be specific to regions in the eye or 526 rare cell types for which we do not yet have representative e/sQTLs. Second, some genes may 527 affect POAG or IOP by perturbing processes only active during development or under specific 528 conditions or stimuli, not captured in adult tissues. Third, the causal variant may be another type of 529 molecular QTL not tested in this study, such as e/sQTL acting in *trans* or protein QTLs. Fourth, 530 some of the genetic associations may be tagging deleterious protein-coding variants⁸. Finally, there are several limitations to Bayesian colocalization methodologies^{52,53}, as described in the 531 532 Supplementary Note.

By applying a novel method (ECLIPSER^{38,39}) to the colocalizing e/sGenes and single 533 534 nucleus expression data from glaucoma-relevant eye tissues, we provided support for previously 535 implicated cell types affecting POAG development, and shed light on less well-established or novel 536 pathogenic cell types for POAG and IOP. One of the unique features of ECLIPSER, compared to other single cell enrichment methods^{72–76} is that it identifies cell types that are specific to a given 537 disease or trait, compared to a range of unrelated complex diseases and traits. Our results found 538 539 that gene expression variation in the ciliary and iris fibroblasts in the unconventional outflow 540 pathway in the anterior segment, in addition to the TM cells and Schlemm's canal cells in the 541 conventional outflow pathway, may both be key contributors to local IOP regulation and POAG risk. 542 The expression profile of the ciliary fibroblasts that was most strongly enriched for POAG genes, is 543 most similar to the 'beam cell A' defined in the single cell RNA-seg atlas of the outflow pathway in van Zyl et al.³⁴ (Fig. S6B in ³⁴), which populates the ciliary muscle and uveal base of the TM: the 544

545 iris fibroblasts are most similar to 'beam cell B', and the TM fibroblasts to the JCT (juxtacanalicular 546 trabecular meshwork) cell type that resides adjacent to the Schlemm's canal. Since the role of the 547 unconventional outflow pathway in IOP homeostasis remains relatively understudied compared to that of the conventional pathway⁷⁷, these findings may encourage further avenues of investigation. 548 Furthermore, the enrichment of IOP genes in pericytes, many of which are not currently associated 549 550 with POAG, extends our understanding of how genetic variation may be affecting IOP in the anterior 551 segment. Pericytes are mural cells that wrap around the endothelial cells that line capillary blood 552 vessels. A recent study has found reduced capillary diameter and impaired blood flow at pericyte locations in mouse eyes with high IOP⁷⁸. 553

554 In the peripheral and macular retina, we found significant enrichment of POAG colocalizing 555 genes in astrocyte and Müller glia cells. Astrocyte and Müller glia are two types of macroglia cells 556 that interact with RGCs and blood vessels, and play an important role in retinal homeostasis, 557 including metabolic supply and structural support, maintaining the extracellular environment of the 558 neurons, and neurotransmitter transmission. Müller glia, the most common glial cell in the retina, 559 span the entire retinal layer, while astrocytes are present only in the innermost layer of the retina. Several studies in animal models and patients with glaucoma^{79–81} have found that astrocytes and 560 561 Müller glia cells become reactive at early stages of glaucomatous conditions when RGCs are intact, 562 suggesting a role for macroglia in the initiation and progression of glaucoma. POAG genes, but not 563 IOP genes, were also enriched in astrocyte types residing primarily in the ONH that contains the 564 lamina cribrosa (LC)⁸², a mesh-like structure where unmyelinated RGCs pass through the sclera to exit the eye, and another in the ONH and optic nerve (ON). Notably, astrocytes have been found 565 to be one of the major cell types isolated from human ONH⁸² and in LC dissected from human 566 567 ONH^{83} , and make up ~20% of the cells in our ONH snRNA-seq dataset.

In the ONH and surrounding posterior tissues, POAG genes were most strongly enriched 568 569 in fibroblasts abundant in the peripapillary sclera (PPS), which surrounds the ONH. Pressure on 570 the ONH and PPS that is a continuum of the LC can cause astrocyte reactivity and compression of RGC axons that can lead to RGC death^{84,85}. Genes mapped to POAG, but not IOP loci were also 571 572 enriched in oligodendrocytes that form a myelin sheath around the axons of RGCs, and 573 oligodendrocyte precursor cells found in the ON, suggesting new IOP-independent mechanisms 574 that can affect optic nerve degeneration. The strongest enrichment for IOP was in vascular 575 endothelial (also enriched for POAG genes) and fibroblast cells primarily residing in the choroid, 576 but also in the ONH and PPS, suggesting that vascular structural abnormalities or functional 577 dysregulation of blood flow to the optic nerve and retina may be an important contributor to POAG⁸⁶. 578 It is also possible that the enrichment in the ONH vascular endothelial cells is capturing causal

579 mechanisms acting in the vascular endothelial cells in the anterior segment that were enriched for 580 most of the same IOP genes as in ONH. The IOP genes were also enriched in vascular smooth 581 muscle cells (VSMC) in the PPS and sclera. These VSMC-specific genes were enriched in lipid 582 binding and negative regulation of cell substrate adhesion processes, suggesting a role in 583 cytoskeleton-associated cell-cell adhesion and cell-extracellular matrix adhesion. These muscle 584 cells may be part of the LC, as LC cells isolated from human ONH were found to stain for alphasmooth muscle actin^{82,83}. Cells in the LC produce extracellular matrix proteins to support the LC 585 586 structure⁸³, and biomechanical strain on the LC, such as from elevated IOP, is thought to be one of the causes of RGC degeneration^{87,88}. Further investigation will be needed to determine whether 587 the muscle cells found in the ONH single nucleus dataset³⁷ reside in the LC or in other structures 588 589 such as blood vessels.

590 Notably, we did not find significant enrichment of cell type-specific expression of POAG or 591 IOP genes in RGCs, whose cell death is the key characteristic of glaucoma, but rather in neuronal 592 support cells. This highlights the importance of targeting the support cells in new therapy design. It 593 should be noted that multiple colocalizing POAG genes are expressed in RGCs (see Supplementary Fig. 20 and Monavarfeshani *et al.*³⁷), however they are also expressed in other 594 595 retinal cell types. Hence, the potential effect of these genes on POAG via RGCs merits further 596 investigation. Furthermore, while several studies have suggested that microglia, specialized macrophage-like cells, may affect RGC survival⁸⁹, we did not find support for a causal role of 597 598 microglia or immune cells in POAG susceptibility. A less expected result was the enrichment of 599 POAG genes in RPE cells, which was also shown in the posterior ocular cell atlas³⁷. In all, our 600 findings in retina, ONH and the surrounding tissues propose cell types and biological processes 601 that may be viable targets for neuroprotective therapies.

602 A potential limitation of our GWAS-cell type enrichment method, ECLIPSER is that it only 603 considers genes that map to genome-wide significant loci and not subthreshold associations. We 604 thus provided further support for our cell type enrichment results using two additional methods. 605 stratified LD score regression and MAGMA, that analyze multiple modest associations genome-606 wide in additional to known GWAS loci. Furthermore, ECLIPSER primarily considers genes whose 607 expression is specific to one or few cell types within a tissue, as the cell type specificity scoring metric was found to be successful in identifying known pathogenic cell types for a range of complex 608 609 diseases and traits in a cross-tissue single nucleus expression atlas using GTEx samples³⁸. We 610 note though that genes expressed at similar levels across most or all cell types may also contribute 611 to disease risk or trait variation and would be missed with this approach.

612 In conclusion, our work has generated new insights into POAG mechanisms, which could 613 inform the development of novel therapies targeting IOP reduction and neuroprotection. By 614 integrating genetic regulation and single cell expression in glaucoma-relevant ocular tissues with 615 GWAS summary statistics we have identified known and new causal genes and biological processes; proposed key ocular cell types that may be pathogenic for glaucoma; and provided 616 617 evidence for the existence of hundreds of novel genetic associations of regulatory effects for glaucoma. In the future, detection of e/sQTLs in relevant eye tissues and at the cellular level^{90,91} is 618 expected to provide a more complete picture of the causal molecular and cellular mechanisms of 619 620 POAG risk and IOP variation.

621

622 Methods

623

624 GWAS datasets. We applied colocalization and fine-mapping analysis to 127 GWAS loci identified 625 in the cross-ancestry POAG GWAS meta-analysis of 34,179 cases and 349,321 controls from European, African, and East Asian populations⁸, 68 GWAS loci from the GWAS meta-analysis of 626 627 the European subset of 16,677 POAG cases and 199,580 controls⁸, and 133 LD-independent 628 GWAS variants in 112 loci from the IOP GWAS meta-analysis of 139,555 primarily UK Biobank 629 (European) samples⁹. The GWAS meta-analysis summary statistics, which included p-value, effect 630 size and standard error, were obtained from the corresponding studies. Chromosome positions were lifted over from genome build 37 (hg19) to hg38. Association results on chromosome X were 631 632 only available for the POAG GWAS meta-analyses (cross-ancestry and European subset).

633

GTEx and EyeGEx QTL datasets. cis-eQTLs and cis-sQTLs from 49 tissues from GTEx release 634 v8²⁶ and *cis*-eQTLs from peripheral retina²⁷ were used in this study. Summary statistics of all 635 636 variant-gene e/sQTL pairs tested in each of the 50 tissues, the significant e/sGenes and e/sVariants at FDR<0.05, and the gene expression levels and LeafCutter⁹² values are available for download 637 from the GTEx portal (URLs). The summary statistics of all variant-gene pairs tested per gene and 638 tissue was used as input to the colocalization analysis, and the LocusZoom⁹³ and LocusCompare 639 plots (URLs). Plots of exon and exon junction read counts were taken from the visualizations on 640 641 the GTEx portal (URLs). GENCODE versions 26 and 25 were used for the GTEx v8 and EyeGEx 642 studies, respectively.

643

644 Enrichment of POAG and IOP associations among e/sQTLs using *QTLEnrich*. To test whether 645 genome-wide significant and nominal POAG and IOP trait associations are enriched among eQTLs

and sQTLs, and to assess the contribution of e/sQTLs to these traits, we applied QTLEnrich^{24,26} to 646 647 the POAG and IOP GWAS meta-analyses summary statistics, using eQTLs and sQTLs from the 49 GTEx tissues^{26,27} and eQTLs from peripheral retina (EyeGEx²⁷). QTLEnrich is a rank and 648 permutation-based method that evaluates the fold-enrichment significance of trait associations 649 650 among a set of e/sQTLs in a given tissue, correcting for three confounding factors: minor allele frequency (MAF), distance to the target gene's transcription start site, and local LD²⁴ (for more 651 652 details see Supplementary Note). Only protein-coding and lincRNA genes were considered in this 653 analysis. Significant tissues were determined based on an Enrichment P-value that passed 654 Bonferroni correction, correcting for 50 tissues and two QTL types tested (P<5x10⁻⁴). The adjusted 655 fold-enrichment was used to rank the significantly enriched tissues, as this statistic is not correlated with tissue sample size or number of significant e/sQTLs per tissue²⁴, as observed with the 656 657 colocalization analysis (Supplementary Fig. 4). For the significant trait-tissue pairs, the fraction and 658 number of e/sVariants proposed to be associated with POAG or IOP were estimated using an 659 empirically derived, true positive rate (Adj. π_1) approach that we implemented in the latest version of QTLEnrich (URLs), based on Storey's analytical $\pi_1^{94,95}$ and an empirical FDR method^{94,95} (see 660 661 Supplementary Note).

662

663 **Colocalization analysis.** To identify a high confidence set of genes and regulatory mechanisms 664 (e/sQTLs) that may be mediating the functional mechanisms underlying known common variant associations with POAG and IOP, we applied two Bayesian-based colocalization methods: 665 eCAVIAR⁴¹ and *enloc*⁴². These methods assess the probability that co-occurring GWAS and 666 667 e/sQTL signals are tagging the same causal variant or haplotype, accounting for local LD and allelic 668 heterogeneity, using slightly different fine-mapping and colocalization approaches. They are 669 applied to GWAS and QTL summary-level statistics enabling the analysis of large, well-powered GWAS meta-analyses, for which genotype data are not available. For the enloc analysis, DAP-G⁴² 670 671 was used to perform fine-mapping of GWAS and e/sQTL loci to estimate the posterior probabilities 672 of each variant in each locus being the causal variant, while eCAVIAR has the fine-mapping feature 673 built in. We applied the two colocalization methods to 127 POAG cross-ancestry GWAS, 68 POAG 674 GWAS loci from the European subset meta-analysis, and 133 independent IOP variants (112 loci) 675 from a primarily European study (described above). Z-scores from the GWAS and GTEx e/sQTL 676 studies, computed as the effect size (beta) divided by the standard error of the effect size for each 677 variant, were used as input into eCAVIAR and DAP-G. For the retina eQTLs, we computed z-scores 678 from the variant association p-values assuming a chi-square distribution with 1 degree of freedom.

679 All GWAS loci were tested for colocalization with all eQTLs and sQTLs from 49 GTEx 680 tissues²⁶ and peripheral retina eQTLs²⁷ that had at least 5 e/sVariants (FDR<0.05) within the GWAS 681 locus LD interval. An LD window around each lead GWAS variant was defined as the chromosome positions on either side containing variants within $r^2 > 0.1$, determined using 1000 Genomes Project 682 Phase 3⁹⁶ as the reference panel, and extending an additional 50kb on either side. For the IOP and 683 684 POAG EUR loci, LD was computed using only the European samples in 1000 Genomes Project, 685 while for the cross-ancestry POAG loci, LD was computed using the European, African, and East 686 Asian samples in 1000 Genomes. If a GWAS variant was not found in 1000 Genomes, an LD proxy variant ($r^2 > 0.8$) was searched for in GTEx, and if not found, the nearest variant was used. The 687 interval boundaries and number of variants tested are reported in Supplementary Tables 7-13. 688 689 eCAVIAR and enloc analyses were applied to all common variants (MAF>1%) that fell within the 690 GWAS LD intervals and were present in both the GWAS and e/sQTL studies. The effect allele of 691 the variants in each GWAS was aligned relative to the alternative (ALT) allele that was used as the 692 effect allele in GTEx and EyeGEx. Colocalization analysis of the retina eQTLs was only performed 693 using eCAVIAR. GWAS-e/sQTL-tissue combinations with a colocalization posterior probability 694 (CLPP) above 0.01 were considered significant with eCAVIAR and/or with an RCP above 0.1 were 695 considered significant with *enloc* based on the methods' recommendations^{41,42,52}. To remove 696 potential false positives, we filtered out variant, gene, tissue, trait combinations where the e/sVariant with a significant colocalization result had a GWAS p-value above 1x10⁻⁵ or whose 697 698 e/sQTL p-values was above 1x10⁻⁴ and/or did not pass FDR<0.05 (FALSE in column 'Pass QC QTL FDR05 P1E04 GWAS P1E05' in Supplementary Tables 7-12). Further details 699 700 on the eCAVIAR and *enloc* analyses and quality control can be found in Supplementary Note.

701 **Mendelian randomization (MR).** Mendelian randomization (MR)⁵¹ was used to provide additional 702 genetic support for a causal relationship between colocalizing e/sQTLs and POAG and/or IOP loci. 703 Significant e/sVariants were used as the instrumental variable (IV) in MR to facilitate causal 704 inference⁹⁷ (See Supplementary Note). Two sample MR was applied to the summary statistics of the e/sQTLs (exposure) and POAG or IOP GWAS (outcome) for all significant colocalizing loci 705 (Supplementary Tables 7-12), using the TwoSampleMR and MendelianRandomization packages 706 in R (version 4.1.2)⁹⁸. To avoid confounding by ancestry, MR was conducted using the European 707 708 ancestry subset of the POAG GWAS and the IOP GWAS, which primarily contains European 709 individuals. MR estimates were generated by calculating the Wald ratio, i.e., the variant-outcome association beta divided by the variant-exposure association beta⁹⁹. Where multiple variants 710 711 constituted the instrument for the candidate gene, the inverse-variance weighted (IVW) method

712 was used as the primary method for pooling variant-specific estimates¹⁰⁰. Given that the IVW 713 approach assumes no horizontal pleiotropy, methods robust to violation of the exclusion-restriction 714 assumption were used as sensitivity analyses. The simple-median¹⁰¹, weighted-median¹⁰¹, MR-Egger¹⁰², and MR-PRESSO¹⁰³ methods were applied. Horizontal pleiotropy was tested using the 715 716 Egger-intercept test and the MR-PRESSO global heterogeneity test, for which P < 0.05 indicated 717 the presence of horizontal pleiotropy. MR associations with Benjamini-Hochberg (BH) FDR < 0.05 718 for the primary IVW/Wald ratio test were considered statistically significant. In cases where 719 horizontal pleiotropy was found based only on the MR-PRESSO global heterogeneity test, an MR 720 PRESSO outlier-corrected p-value < 0.05 was considered a significant result.

721 Integration of retina Hi-C and epigenetic data with colocalizing POAG loci and e/sQTLs. To 722 identify retina eQTLs or GTEx e/sQTLs that colocalized with POAG GWAS loci that may be exerting 723 their causal effect on POAG in the retina, we inspected all POAG loci in the context of chromatin 724 loops, cis regulatory elements (CREs) and super-enhancers (SEs) that were previously detected in retina from 5 postmortem non-diseased human donor eyes⁴⁰. The loops were calculated from 725 Hi-C (3D chromosome conformation capture) data, and the CREs and SEs from epigenetic data. 726 as described in Marchal et al.⁴⁰. The lead POAG GWAS variants and their LD proxy variants 727 728 (r²>0.8), the colocalizing e/sQTLs and LD proxy variants, which are also significant e/sVariants 729 (FDR<0.05), and the e/sQTL target genes were inspected for overlap or closest overlapping gene with the Hi-C loops, CREs, and SEs, using the closestBed command from bedtools (v2.27.1)¹⁰⁴. 730 731 For retina eQTLs and GTEx e/sQTLs GENCODE versions 25 and 26 were used, respectively, to 732 overlap genes and TSS hg38 coordinates. Colocalizing e/sQTLs were proposed as putative causal 733 genes to POAG, if the e/sVariant overlapped one foot of the loop and the second foot overlapped 734 the gene body or TSS of the target gene. CRE and SE target genes were defined if the e/sVariant 735 and gene body or TSS of the gene overlapped the same CRE or SE. The closest target genes 736 identified using chromatin loops for the POAG cross-ancestry GWAS loci was taken from our 737 recently published Hi-C study (Supplemental Data 4 in Marchal et al.⁴⁰).

738

Single nucleus RNA-seq datasets and differential gene expression. We analyzed gene expression values (log(TPK+1)) from four single-nucleus (sn) RNA-seq data sets from the following glaucoma-relevant regions of the eye: anterior segment³⁶, retina^{33,36}, macula³⁶, and optic nerve head and surrounding posterior tissues³⁷. All tissue samples were dissected from non-diseased eye globes from post-mortem donors with no record of eye disease, and were de-identified. The number of cells per cell types in each of the tissues can be found in Supplementary Table 38.

Differential gene expression was applied to genes expressed in at least 5% of cells in any cell type
 cluster in each of the datasets. Here is a brief description of the four datasets:

747 Anterior segment: Six tissues in the anterior segment, including central cornea, corneoscleral wedge (CSW), trabecular meshwork (TM), iris, ciliary body (CB) and lens, were 748 dissected from six donors within 6 hours from death, as described in³⁶. To be able to compare 749 750 across cell types between tissues in the anterior segment, the snRNA-seg data from cornea, CSW, 751 CB, iris, and TM were pooled, downsampled to 1000 cells per type in each tissue, and reclustered 752 yielding 34 clusters³⁶. Five clusters were identified for the lens. Differential gene expression analysis between each cell type and all other cell types was performed using the regression model 753 in MAST¹⁰⁵ that corrects for the proportion of genes expressed per cell. 754

755 Retina: Retina samples from the fovea (4mm punch), macula (6 mm punch) and/or 756 periphery were collected from six donors within 6 hours from death from the Utah Lions Eye Bank. flash frozen and processed as described in³³ (more details in Supplementary Note). The number 757 758 of cells from the three retinal regions from each donor is given in Supplementary Table 35. snRNA-759 seg data from RGCs from a few additional donors were added to the data set, given the relevance 760 of RGCs to glaucoma, though RGCs still only comprised about 1/250 of the total data set. 761 Differential gene expression for each cell type in the ml class level used in this study was computed 762 using the Wilcoxon rank sum test.

Macula: Macular samples were dissected with 8mm punches from five donors within 4 hours of death at the University of Utah (Supplementary Table 36). For three of the samples, RGCs were enriched by staining the nuclei with NEUN antibody (Millipore Sigma, #FCMAB317PE) followed by FACS sorting. The macular samples were processed similarly to the optic nerve head samples below. Differential gene expression for each cell type compared to all other cell types was computed using the MAST method¹⁰⁵.

769 Optic nerve head and posterior tissues: The optic nerve head, including peripapillary 770 tissues, was dissected with 4 mm punches from 13 donors, the optic nerve was dissected from 7 771 donors, peripapillary sclera from 4 donors, sclera from 3 donors, and choroid from 5 donors, within 772 a median of 6 hours from death at either the University of Utah or Massachusetts General Hospital 773 (Supplementary Table 37). Further description of the tissues' dissection, single-nuclei isolation, and snRNA-sequencing can be found in Supplementary Note and Monavarfeshani et al.³⁷. snRNA-seq 774 775 data processing and analyses were performed similarly to the pipeline used for the anterior 776 segment in van Zyl et al.³⁶. Thirty-six cell type clusters were identified across the five tissues. 777 Differential gene expression (DGE) was computed using the MAST method¹⁰⁵, comparing the cells 778 from each cell type to all other cells, excluding cells from the same cell class similar to the cell type

of interest, aside for the given cell type (e.g., excluding all fibroblast cell types when computingDGE for cell type, 5-Fibro).

781

782 Cell type-specific enrichment of genes that map to GWAS loci for a given complex trait using 783 **ECLIPSER.** To identify ocular cell types that are enriched for cell type-specific expression of genes 784 mapped to GWAS loci of POAG, IOP and related traits, we extended a method we recently 785 developed called ECLIPSER (Enrichment of Causal Loci and Identification of Pathogenic cells in Single Cell Expression and Regulation data)^{38,39}, to target genes of colocalizing e/sQTLs. 786 787 ECLIPSER assesses whether genes mapped to a set of GWAS loci for a given complex disease 788 or trait are enriched for cell type-specific expression compared to the cell type specificity of genes 789 mapped to a background (null) set of GWAS loci associated with hundreds of unrelated traits. The 790 underlying assumption of ECLIPSER is that multiple (though not necessarily all) trait-associated 791 genes will be more highly expressed in a given pathogenic cell type compared to non-pathogenic 792 cell types in a tissue of action, more so than unrelated traits. The analysis consisted of the following 793 main steps: (i) Mapping genes to GWAS loci. For the POAG and IOP traits, e/sQTL colocalization 794 analysis was used to prioritize genes in GWAS loci. For the cornea-related, VCDR and negative 795 control traits, genes were mapped to GWAS loci if they were target genes of a GTEx or retina 796 e/sQTL that was in LD (r^2 >0.8) with the GWAS locus (since colocalization analysis for these traits 797 was beyond the scope of this paper). The genome-wide significant variants associated with the 798 cornea traits and negative control traits were taken from Open Targets Genetics¹⁰⁶, and for 799 physician and machine learning-based VCDR measures from the corresponding published GWAS 800 meta-analyses^{12,13}. (ii) Null set of GWAS loci. We compiled a null set of GWAS loci, by selecting 801 all genome-wide significant associations for a range of complex traits in Open Targets Genetics¹⁰⁶ 802 that were taken from the NHGRI-EBI GWAS catalog and UK Biobank GWAS studies. We excluded 803 from the null set variants associated with any ocular trait. (iii) LD clumping of loci. We collapsed 804 GWAS variants that were in LD with each other (r^{2} >0.8) or that shared a mapped gene into a single 805 locus for the set of GWAS loci for each ocular or negative control trait and for the null set, 806 separately, to avoid inflating the cell type enrichment results due to LD³⁹. (iv) Cell type specificity 807 locus score. We scored each GWAS locus for the ocular traits and the null set as the fraction of 808 genes mapped to the locus, that demonstrated cell type specificity (defined here as fold-change > 809 1.3 and FDR < 0.1). Only genes expressed in at least 5% of cells in any cell type cluster were 810 included in the analysis. (v) Assessing cell type-specificity of GWAS locus set. We estimated 811 a cell type specificity fold-enrichment and p-value per trait (GWAS locus set), tissue and cell type 812 combination, compared to the null GWAS locus set, using a Bayesian Fisher's exact test and the

95th percentile of the null locus scores for the cell type specificity cutoff. The Bayesian approach 813 814 enables estimating 95% confidence intervals of the fold-enrichment, including for traits that have few or no loci that fall above the enrichment cutoff³⁹. (vi) Cell type specific disease-contributing 815 genes. Cell type-specific genes mapped to GWAS loci whose score was equal to or above the 95th 816 817 percentile enrichment cutoff in significantly enriched cell types ('leading edge loci') were proposed 818 to influence the given complex trait in the given cell type ('leading edge genes'), though it is possible 819 that some of these genes are affecting the given trait through other cell types. Cell types with a 820 tissue-wide Benjamini-Hochberg FDR equal to or below 0.1, correcting for the number of cell types 821 tested per tissue, were considered significantly enriched for genes associated with a given trait. To 822 test the specificity of ECLIPSER, we applied the method to eight negative control traits listed in 823 Supplementary Table 45. To assess the robustness of the cell type enrichment results with 824 ECLIPSER, we ran two additional cell type enrichment methods of GWAS data that consider 825 genome-wide genetic associations beyond genome-wide significant loci: stratified LD score regression²⁵ and MAGMA¹⁰⁷ (see below). 826

827

828 Cell type specific heritability enrichment of disease associations using stratified LD score regression. We applied stratified LD score regression (S-LDSC)²⁵ (v1.0.1; URLs) to the GWAS 829 830 summary statistics of the POAG cross-ancestry meta-analysis, POAG European subset meta-831 analysis and IOP meta-analysis, and the four single-nucleus differential gene expression datasets 832 described above, to evaluate the contribution of genetic variation in cell type-specific genes to trait heritability. Common variants (MAF>1%) within or near genes specifically expressed in the different 833 834 cell types (fold-change > 1.1 and FDR<0.1) in each of the four single-nucleus eye tissue datasets 835 described above, were considered in the S-LDSC analysis. A 100 kb windows on either side of each gene was used. The European samples in 1000 Genomes Project Phase 3⁹⁶ were used as 836 837 the reference panel for computing the LD scores for all three GWAS meta-analyses. Heritability 838 enrichment per cell type was considered significant at Benjamini-Hochberg FDR below 0.1.

839

MAGMA gene-association correlation with cell type gene expression. We applied the regression-based model MAGMA (v1.10)¹⁰⁷ to the POAG cross-ancestry, POAG European subset, and IOP GWAS meta-analyses and the four single-nucleus ocular expression datasets described above, which tests for association between gene association z-scores and average gene expression per cell type, controlling for average gene expression across all cell types per tissue. Gene-based association z-scores were computed for each GWAS based on the most significant variant (SNP-wise=top) within 100kb around each gene, as described in de Leeuw *et al.*¹⁰⁸. The

European samples in 1000 Genomes Project Phase 3⁹⁶ were used as the reference panel for the 847 848 POAG EUR and IOP GWAS, while all five populations (EUR, AFR, AMR, EAS, SAS) were used 849 for the POAG cross-ancestry GWAS. Significance was determined at Benjamini-Hochberg FDR 850 below 0.1. We applied conditional analysis to all pairwise combinations of nominally significant (P<0.05) cell types within a given tissue, to identify cell types whose trait association signals are 851 independent of the other significant cell type¹⁰⁷. A proportional significance (PS) of the conditional 852 853 P-value of a cell type relative to its marginal P-value was computed for each cell type in each cell 854 type pair. Two cell types in a given pair with PS≥0.8 were considered independently associated 855 cell types, and a pair of cell types with PS≥0.5 were considered partial-joint associations. In the 856 case where one cell type had PS \geq 0.5 and the second cell type a conditional P-value \geq 0.05, the 857 first cell type was retained and the second cell type was considered completely dependent on the 858 association of the first cell type. For more details see: https://fuma.ctglab.nl/tutorial#celltype.

859

Gene set enrichment analysis of POAG and IOP associated genes. We used GeneEnrich^{24,26} 860 861 to test whether genes proposed to affect POAG risk or IOP variation cluster in specific biological 862 processes or mouse phenotype ontologies. GeneEnrich assesses enrichment of a set of genes of 863 interest in biological pathways or other types of biologically meaningful gene sets, using a 864 hypergeometric distribution and permutation analysis. To account for biases that could arise from 865 the set of genes expressed in a given tissue, an empirical gene set enrichment P-value was 866 computed as the fraction of 1,000 to 100,000 k randomly sampled genes (k = number of significant 867 genes, e.g., colocalizing e/sGenes) from all genes expressed in the given tissue (background set) 868 that have a hypergeometric probability equal to or higher than that of the significant list of genes. 869 Given the high LD in the HLA region on chromosome 6 (chr6:28510120-33480577) we removed 870 all genes in this region from the gene set enrichment analysis, unless noted otherwise.

871 We applied *GeneEnrich* to three groups of POAG and IOP associated genes: (i) All 228, 872 118, and 279 unique target genes of eQTLs and sQTLs that colocalized with POAG cross-ancestry, 873 POAG EUR, and IOP GWAS loci, respectively. Given that the colocalizing e/sQTLs were derived 874 from the different GTEx tissues and retina, we used all genes expressed in any of the 49 GTEx 875 tissues and retina as the background set of genes, and did not correct for expression levels given 876 the differences in expression levels between the tissues. (ii) Sets of POAG and IOP colocalizing 877 genes that were enriched in specific cell types in the eye tissues based on ECLIPSER analysis 878 (tissue-wide FDR \leq 0.1). For the background sets of genes, we chose all genes expressed in the 879 GTEx or retina tissue that was most relevant for the enriched cell type (e.g., Brain for Optic nerve 880 head; full list in Supplementary Table 39). Given that the expression levels in a tissue may not fully

881 reflect the expression levels in the particular cell type, we did not correct for expression levels in 882 the gene set enrichment analysis of the cell type-specific gene sets. (iii) Target genes of e/sQTLs 883 (FDR<0.05) with top ranked POAG or IOP GWAS P-values (P < 0.05) in tissues whose e/sQTLs 884 were enriched for trait associations based on QTLEnrich. Given that e/sQTLs in most tissues 885 displayed significant enrichment, a selected set of QTL/tissue-trait pairs was chosen for gene set 886 enrichment analysis based on the tissue having a top ranked adjusted fold-enrichment and 887 consisting of cell types that may be relevant to glaucoma pathophysiology, such as cells cultured 888 fibroblasts, brain, and artery (Supplementary Tables 4-5). The background sets of genes were 889 defined as all genes expressed in the given tissue excluding the target genes of e/sQTLs with 890 GWAS P<0.05. The expression levels of the randomly sampled genes from the background set in 891 the permutation analysis were matched on the expression levels of the significant set of genes.

892 We applied GeneEnrich to over 11,000 gene sets from four databases downloaded from 893 MSigDB (URLs): Gene Ontology (GO) with three domains: biological processes, molecular 894 function, and cellular components; Reactome; Kyoto Encyclopedia of Genes and Genomes 895 (KEGG); and mouse phenotype ontology gene sets from the Mouse Genome Informatics (MGI). 896 Only gene sets with 10 to 1000 genes were tested, and only genes that were found in the given 897 database were included in the analysis. Statistical significance was determined using a Benjamini 898 Hochberg FDR below 0.1 per database, given extensive gene set overlap between databases. 899 Gene sets with empirical gene set enrichment below 0.05 were considered nominally significant. 900

901 Conditional analysis of MYOC POAG locus. Given our finding of significant colocalization of a 902 PIGC sQTL with the POAG cross-ancestry association signal in the GWAS locus rs74315329, 903 whose lead variant is a nonsense mutation in the MYOC gene, we tested whether there was a 904 secondary independent signal in this locus that might colocalize with the PIGC sQTL. We 905 performed association testing on all variants on chromosome 1 conditioning on rs74315329, the 906 lead POAG GWAS variant in the locus by applying the tool COJO (URLs) to the POAG cross-907 ancestry GWAS meta-analysis summary statistics on chromosome 1. To maintain the MYOC lead 908 variant in the initial association testing we filtered out variants with MAF<0.0001. The effective 909 sample size of the POAG cross-ancestry GWAS was computed based on the equation: 4/[(1/Ncases)+(1/Ncontrols)]¹⁰⁹, which yielded N=124,531 for the POAG GWAS cross-ancestry 910 911 meta-analysis⁸. For the variant allele frequencies required as input to COJO, we used the 912 European, African and East Asian samples in 1000 Genomes Project⁹⁶, as the POAG GWAS meta-913 analysis is comprised of these three ancestral groups. eCAVIAR and enloc were applied to the 914 residual statistics in the MOYC locus from the conditional analysis and all overlapping e/sQTLs

from the GTEx tissues and retina. To remove potential false positives, we filtered out variant, gene, tissue, trait combinations if the e/sVariant with a significant colocalization result had a GWAS pvalue above 2x10⁻⁵ or an e/sQTL p-value above 1x10⁻⁴ and/or an FDR above 0.05 (FALSE in column 'Pass_QC_QTL_FDR05_P1E04_GWAS_P2E05' in Supplementary Tables 25 and 27). We used a slightly more lenient GWAS p-value cutoff for the conditional analysis (P<2x10⁻⁵ compared to P<1x10⁻⁵ used for the original GWAS summary statistics) given the reduced association power

- 921 of conditional analysis.
- 922

923 Data availability

924 All GTEx protected data are available through the database of Genotypes and Phenotypes (dbGaP) 925 (accession no. phs000424.v8). The GTEx eQTL and sQTL and EyeGEx retina eQTL summary 926 statistics are available on the GTEx portal (https://gtexportal.org/home/datasets). The snRNA-seq 927 data for the anterior segment and macula are available in Gene Expression Omnibus (GEO) 928 accession number GSE199013, for the optic nerve head and posterior tissues in GSE236566, and 929 for the retina in GSE226108. The processed data of the anterior and posterior segments can be 930 visualized in the Broad Institute's Single Cell Portal at https://singlecell.broadinstitute.org/single_cell/study/SCP1841 931 and 932 https://singlecell.broadinstitute.org/single cell/study/SCP2298. The retina Hi-C data is accessible 933 in GEO accession number GSE202471. The GWAS summary statistics for the POAG cross-934 ancestry GWAS meta-analysis and European subset meta-analysis are accessible in GEO under 935 accession numbers GCST90011770 and GCST90011766, respectively, and for IOP are available 936 from the corresponding publication (Khawaja et al., Nature Genetics 2018). The GWAS loci for 937 complex traits analyzed in this study were downloaded from Open Targets Genetics (https://genetics.opentargets.org/). The gene sets taken from MSigDB were downloaded from: 938 939 http://www.gsea-msigdb.org/gsea/msigdb/collections.jsp, and the mouse phenotype ontology gene 940 sets from the Mouse Genome Informatics (MGI) website (http://www.informatics.jax.org/).

941

942 Code Availability

- The code of all tools used for analyses in this paper are publicly available and are listed in the URLs
 below. Custom code used to generate some of the plots are available upon request.
- 945
- 946 URLs
- 947 GTEx: <u>https://gtexportal.org/home/datasets</u>
- 948 EyeGEx: <u>https://gtexportal.org/home/datasets</u>

- 949 QTLEnrich v2: <u>https://github.com/segrelabgenomics/QTLEnrich</u>
- 950 GeneEnrich v2: <u>https://github.com/segrelabgenomics/GeneEnrich</u>
- 951 MSigDB: <u>http://www.gsea-msigdb.org/gsea/msigdb/collections.jsp</u>
- 952 PLINK: <u>https://www.cog-genomics.org/plink/</u>
- 953 eCAVIAR: https://github.com/fhormoz/caviar
- 954 fastEnloc: <u>https://github.com/xqwen/fastenloc</u>
- 955 DAP-G: https://github.com/xqwen/dap/tree/master/dap_src
- 956 ECLIPSER: <u>https://github.com/segrelabgenomics/ECLIPSER</u>
- 957 MAGMA v1.10: <u>https://ctg.cncr.nl/software/magma</u>, <u>https://fuma.ctglab.nl/tutorial#celltype</u>
- 958 S-LDSC v1.0.1: https://github.com/bulik/ldsc
- 959 genomAD: <u>https://gnomad.broadinstitute.org/</u>
- 960 QMplot: https://github.com/ShujiaHuang/qmplot
- 961 LocusCompare: https://github.com/boxiangliu/locuscomparer
- 962

963 Acknowledgements

- 964 We thank William Wen for helpful discussions on the interpretation of the colocalization results. We 965 thank members of the Searè lab for valuable comments and feedback. This work was funded by 966 NIH/NEI R01 EY031424-01 (AVS, ARH, JR, PAM), NIH/NEI P30 EY014104 (JLW, AVS), NIH/NEI 967 EY032559-01 (JLW, AVS), and the Chan Zuckerberg Initiative (CZI) Seed Network for the Human 968 Cell Atlas awards CZF2019-002459 (JRS, AVS, WY, AM) and CZF2019-002425 (QL, RC). XJ is 969 supported by the University of Edinburgh and University of Helsinki joint PhD studentship program 970 in Human Genomics. VV is supported by an MRC University Unit Programme grant 971 (MC UU 00007/10) (QTL in Health and Disease). APK is supported by a UK Research and Innovation Future Leaders Fellowship, an Alcon Research Institute Young Investigator Award and 972 973 a Lister Institute for Preventive Medicine Award. This research was supported by the NIHR 974 Biomedical Research Centre at Moorfields Eve Hospital and the UCL Institute of Ophthalmology.
- 975

976 Competing interests

- APK has acted as a paid consultant or lecturer to Abbvie, Aerie, Allergan, Google Health,Heidelberg Engineering, Novartis, Reichert, Santen and Thea.
- 979
- 980
- 981
- 982





Figure 1. Analysis workflow from POAG and IOP GWAS to causal regulatory mechanisms, genes, pathways, and cell types. a, POAG and IOP associations genome-wide (known and modest associations) were tested for enrichment among e/sQTLs in GTEx tissues and retina compared to permuted null sets of variants matched on confounding factors, using QTLEnrich. In cases where enrichment was found, the lower bound number of e/sQTLs in a given tissue, likely to be true trait associations was estimated using an empirically derived, true positive rate (π_1) approach. b, Putative causal genes were prioritized per known POAG and IOP GWAS locus by applying two colocalization methods to all e/sQTLs from 49 GTEx tissues and retina eQTLs that overlapped each locus. A Manhattan plot of the POAG cross-ancestry GWAS meta-analysis was plotted with QMplot (URLs). c, All target genes of significantly colocalizing e/sQTLs per trait were tested for enrichment in signaling and metabolic pathways (Reactome, KEGG), gene ontologies and mouse phenotype ontologies using GeneEnrich. d, Significantly colocalizing e/sGenes were tested for enrichment in specific cell types in single nucleus RNA-seq data of glaucoma-relevant eve tissues, using ECLIPSER. Cell type specific genes were defined with cell type fold-change >1.3 and FDR<0.1 per tissue. Cell type specificity significance per GWAS locus set for a given trait was assessed against a null distribution of GWAS loci associated with unrelated, non-ocular traits. using a Bayesian Fisher's exact test. Genes mapped to GWAS loci with a cell type specificity score above the 95th percentile of null locus scores were proposed as contributing to the trait in the enriched cell type. e, Cell type enrichment for the POAG and IOP GWAS was corroborated using two regression-based methods that assess cell type specificity of trait associations considering all associations genome-wide: stratified-LD score regression and MAGMA.

- _____

Figure 2



Figure 2. Enrichment and colocalization analysis of eQTLs and sQTLs with POAG and IOP associations. a, b Quantile-quantile (Q-Q) plots of POAG cross-ancestry (a) and IOP (b) GWAS -log₁₀ (P-value) compared to expectation for the best eQTL per eGene sets (eVariants with FDR < 0.05) of the top enriched tissues based on adjusted fold-enrichment (colored points), compared to all variants in the GWAS (black points). Grev line represents the diagonal, c. Histogram of percent of GWAS loci with at least one colocalizing e/sQTL (eCAVIAR CLPP > 0.01 and/or enloc RCP > 0.1) for the three traits (POAG cross-ancestry, POAG European (EUR) ancestry subset, and IOP European ancestry). Numbers above the bars represent the number of loci with at least one colocalizing e/sQTL. Red, dark blue, and light blue bars indicate percentage of loci with at least one colocalizing eGene, sGene, or both, respectively. d, Scatter plot comparing unique number of e/sGenes per locus that significantly colocalized per locus versus unique number of e/sGenes tested per locus. Points are color-coded by number of GWAS loci. The black line represents the diagonal. e, Violin plots showing the distribution of the unique number of colocalizing eGenes (red), sGenes (dark blue), or both (light blue) per locus for the three GWAS tested. The center line in the box plots contained within each violin plot shows the median and the box edges depict the interguartile range. f. Stacked histogram showing the number of colocalizing e/sGenes per gene biotype for each GWAS. Protein coding (light blue), lincRNA (brown), antisense (grey), pseudogenes (yellow), and other (dark blue).

Figure 3

chr1:171636338:G:A rs74315329	PIGC	e s 🔺				•																					
	RP11-466F5.8	e 🔵	•	•		•				• (•	• C				(00		•	•	00	00		0	• •		
chr1:165768467:G:C rs2790053	TMCO1	e • s •	•	•		•				• (•	•		•			•				00)		•			
	RP11-149I2.4	s																	•								
chr9:22051671:G:C rs944801	CDKN2B-AS1	s																	•					4			
	CDKN2A	е				•																					
chr9:104933258:C:T rs2472494	RP11-217B7.2	e OO	000	000			•	•••			•	00		00)•	0	•	00)0	0	00	00		
chr9:110549951:G:C rs61751937	TXNDC8	s																						•			
chr4:7902636:G:A	HTRA3	е				•					•						•				•						
rs938604	AFAP1	е			•	•						•					•				•						
chr17:10127866:G:A rs9913911	GAS7	е		*							*																
	LMX1B	e 🗷																						•			
	RP11-123K19.1	e 🔵																									
chr9:126628521:C:T rs3829849	RP11-205K6.1	е																									
	MVB12B	e s																				1				•	
	FAM83A-AS1	e s											•								•						
chr8:123542077:T:A rs62521288	FAM83A	e s																			•			•		•	OPPOSITE SAME Posterior Probability
	TBC1D31	е						•																•			• 1.00
chr5:56487851:G:A rs112142644	LINC01948	е																								0	0.75 0.50 0.25
	AC000078.5	e • •	• •	• •		•	•		•	•	•	•	••		•	•	_		•		• •	•	• •	•		•	0.01 Method
chr22:19882624:C:T rs8141610	TXNRD2	e OO s • •	000			•	00(•()	•		C)•(•)		00)•(•		•	© eCAVIAR △ fastENLOC □ Union
	C22orf29	e • •	••	•		•	•••	•••	•	•	•	•	•••	•••	•	•			•		0	•	• •	•		•	CLPP/RCP > 0.5 CLPP > 0.01 BCP >
chr7:116522252:T:A	CAV2	e s	•									•		•				(•			•			Not sig
1810257125	AC002066.1	e										•															
	PRSS23	e 🔸 🔸									•			•					•								
	CTD-2005H7.1	e • •									•																
chr11:86657064:C:T rs10792871	MEQ	е • •									•								•								
	WE5	s • •									•			•			_		•	•							
	RP11-762L8.6	e •									•						_										
chr16:77627835:C:T rs280875 chr3:85123214:G:C rs13101042	NUDT7 CADM2	e											•				•										
chr9:133255801:C:T rs8176749	ABO	e 🔺 🛦 s 🔺 🔺	^		•	×	•						•				A E	•	• •	*	• 5						
chr2:55705879:C:T	EFEMP1	s			_									C)												
chr21:25844528:T:A	ATP5J	s	• •			•	••	•••	•	•		00		00		•	•		•		• (•	••	••	•	
chr15:73928957:C:T rs1550437	LOXL1	e		•										C					•				•				
	LOXL1-AS1	e	•	•											•				•					•		•	
chr2:152508013:G:A	AC012066.1	e 🔵																									
rs1579050	LINC02052	s		_																							
chr3:186411027:G:A rs56233426	DGKG	e													,					0							
		Adipose_Subcutaneous Adipose_Visceral_Omentum	Adrenal_Gland- Artery_Aorta	Artery_Coronary Artery_Tibial Brain Amvadala	Brain_Anterior_cingulate_cortex_BA24 Brain_Caudate_basal_ganglia Brain_Caraballar_Hamistharab	Brain_Cortex	Brain_Frontal_Cortex_BA9- Brain_Hippocampus-	Brain_Hypothalamus- ain_Nucleus_accumbens_basal_ganglia-	Brain_Putamen_basal_ganglia Brain_Spinal_cord_cervical_c-1	Brain_Substantia_nigra Breast_Mammary_Tissue	Cells_Cultured_fibroblasts Cells_EBV-transformed_lymphocytes	Colon_Sigmoid- Colon_Transverse-	Esophagus_Gastroesophageal_Junction Esophagus_Mucosa	Esophagus_Muscularis Heart Atrial Appendace	Heart_Left_Ventricle		Muscle_Skeletal Narva Tihial	Ovary	Pancreas. Pituitary-	Prostate- Retina-	Skin_Not_Sun_Exposed_Suprapubic- Skin_Sun_Exposed_Lower_led-	Small_Intestine_Terminal_Ileum	Stomach	Testis- Thyroid-	Uterus	Whole_Blood	34

Figure 3. Colocalizing e/sQTLs in GTEx tissues and retina with top POAG GWAS loci. Genes with at least one significant colocalization result are shown for e/sQTLs tested across 49 GTEx tissues and peripheral retina for the top 21 POAG cross-ancestry GWAS loci. GWAS loci were ordered by absolute value of their effect size. Within each locus, genes were ordered based on their chromosome position. Bubble size is proportional to the maximum colocalization posterior probability of all e/sVariants tested for the given gene, QTL type and tissue combination. Points are color-coded by direction of effect (blue if increased expression or splicing increases POAG risk or vice versa; red if increased expression or splicing decreases POAG risk or vice versa). Shape of points indicates colocalization method used: circle (eCAVIAR), triangle (enloc), and square (tested in both methods; results shown for method with maximum posterior probability). Grey or black border denotes variant-gene-tissue-QTL combination that passed QC filtering (Methods) and a colocalization posterior probability cutoff above 0.01/0.1 (CLPP/RCP) or 0.5 (higher confidence). respectively. White or black asterisk in the square indicates whether the second method tested passed a posterior probability cutoff 0.01/0.1 (CLPP/RCP) or 0.5, respectively.

Figure 4



Figure 4. Examples of colocalizing e/sQTLs with top POAG and IOP GWAS loci. a, 1217 1218 Colocalization results for all e/sGenes tested in the POAG cross-ancestry rs2790053 locus LD 1219 interval with ≥ 1 significant eQTL or sQTL result across 49 GTEx tissues and peripheral retina based 1220 on eCAVIAR and/or enloc. Genes were ordered by chromosome position. Size of points is 1221 proportional to the maximum colocalization posterior probability of all e/sVariants tested for the 1222 given gene, QTL type and tissue combination. Points are color-coded by direction of effect (blue if 1223 increased expression or splicing increases POAG risk or vice versa; red if increased expression or 1224 splicing decreases POAG risk or vice versa). Shape of points indicates colocalization method: circle 1225 (eCAVIAR), triangle (enloc), and square (tested in both methods; results shown for method with 1226 maximum posterior probability). Grey or black border denote variant-gene-tissue-QTL combination 1227 that passed QC filtering (Methods) and a colocalization posterior probability cutoff above 0.01/0.1 1228 (CLPP/RCP) or 0.5, respectively. White or black asterisk in the square indicates whether the 1229 second method tested passed a posterior probability cutoff of 0.01/0.1 (CLPP/RCP) or 0.5, respectively. b, LocusZoom⁹⁶ plot for TMCO1 sQTL -log₁₀(P-value) in GTEx Cells Cultured 1230 1231 fibroblasts in the POAG cross-ancestry GWAS variant rs2790053 (chr1 165768467 C G b38) LD 1232 interval. Points are color-coded by LD (r^2) relative to the lead GWAS variant. **c**,**d** LocusCompare 1233 plot of -log₁₀(P-value) of the POAG cross-ancestry GWAS meta-analysis versus the -log₁₀(P-value) 1234 of the Cells Cultured fibroblast sQTL or eQTL acting on TMCO1 (c) or RP11-466F5.8 (d), respectively. Points are color-coded based on LD (r^2) relative to the variant with the highest 1235 1236 eCAVIAR colocalization posterior probability (CLPP). e. Violin plot of normalized intron-excision ratio for chr1:165768269-165768482 computed with Leafcutter⁹⁵ for TMCO1 in Cells Cultured 1237 fibroblasts as a function of the genotype of the sVariant chr1 165817713 G A b38 (rs143863391) 1238 1239 with the highest CLPP (0.92) for this sQTL and the POAG cross-ancestry GWAS locus rs2790053. 1240 The effect size of the sQTL relative to the alternative allele (beta = -0.43) is in opposite direction 1241 relative to the GWAS variant (beta = 0.25), suggesting that decreased splicing between 1242 chr1:165768269-165768482 increases POAG risk. f, Gene model for TMCO1 in GTEx fibroblasts 1243 on the negative strand showing all intron excision splicing events detected with Leafcutter in 1244 TMCO1. A zoom in of the splicing event (chr1:165768269-165768482; red), an alternative splice 1245 donor site on exon 4 (red versus blue or green), associated with the sVariant 1246 chr1 165817713 G A b38 that colocalized with POAG risk is shown. A longer exon 4 in TMCO1 1247 is associated with decreased risk of POAG. q. TMCO1 gene model and transcripts expressed in Cells Cultured fibroblasts taken from the GTEx portal (URLs). In the gene model, exon boxes are 1248 1249 color-coded by exon read counts per base (blue) and lines connecting exons are color-coded by 1250 exon-exon junction read counts (red). All splicing events observed in the tissue are shown,

1251	including the alternative splice event between exon 4 and exon 5 whose genetic regulation
1252	colocalized with POAG (c). Below the gene model, transcript expression in Cells Cultured
1253	fibroblasts in Transcripts per Million (TPM), computed with RSEM ¹¹⁰ , is shown in descending order.
1254	
1255	
1256	
1257	
1258	
1259	
1260	
1261	
1262	
1263	
1264	
1265	
1266	
1267	
1268	
1269	
1270	
1271	
1272	
1273	
1274	
1275	
1276	
1277	
1278	
1279	
1280	
1281	
1282	
1283	
1284	







chr6:133,982,864-134,072,579

- 11

Figure 5. Chromatin loops and regulatory elements in human retina support effect of colocalizing e/sQTLs on POAG risk. a, Retina CREs (cyan) derived from epigenetic data overlapping e/sVariants that colocalized with POAG associations in the CDKN2A/B locus. The lead POAG variants from the cross-ancestry (blue line) and European subset (orange line) GWAS are shown in the top track, followed by their linkage disequilibrium (LD) proxy variants (r^{2} >0.8) in the track below. The significantly colocalizing CDKN2B-AS1 sVariants in Pituitary, CDKN2A eVariants in Brain Cortex, and CDKN2B eVariants in Skeletal Muscle are represented by red lines, and the grey lines represent LD proxy variants that are also significant e/sQTLs (FDR<0.05) for the corresponding gene and tissue. b, Retina CREs (cyan) overlapping retina SLC2A12 eVariants that colocalized with the POAG cross-ancestry association. Tracks display the lead POAG cross-ancestry GWAS variant (orange) and its LD proxy variants (grey), followed by the significantly colocalizing SLC2A12 retina eVariants (red) with their LD proxy eVariants that are also significant eQTLs at FDR<0.05 (grey). The CRE overlaps the promoter of SLC2A12. c, Retina chromatin loops from Hi-C data, SEs (blue), and CREs (cyan) shown for the RERE POAG locus. Tracks display the lead POAG cross ancestry GWAS variant (orange) and its LD proxy variants (grey), followed by significantly colocalizing RERE eVariants in Nerve Tibial, RERE sVariants in fibroblast cells, and RERE-AS1 eVariants in Adipose Subcutaneous (red), and their LD proxy variants that are also significant e/sQTLs (FDR<0.05) for the corresponding gene and tissue (grey). Magenta loops have one foot that overlaps or is in LD with the POAG variant and colocalizing e/sQTLs. In all panels, LD proxy variants were computed at r²>0.8, TADs are represented as solid black lines, and the magenta heatmaps represent Hi-C physical contact maps. CRE, Cis-regulatory element; SE, Super-enhancer; TAD, Topologically associating domain.



1385 Figure 6. Cell type enrichment of e/sQTL-mapped genes for POAG, IOP and related trait loci 1386 in the anterior segment of the eye. a, Significance (circle size, -log10(P-value)) and fold-1387 enrichment (circle color) of the cell type specificity of GWAS locus sets for POAG cross-ancestry. POAR European subset, IOP, central cornea thickness, corneal hysteresis, physician-defined 1388 1389 ratio vertical-cup-to-disc (VCDR), and machine learning (ML)-defined VCDR 1390 (VCDR ML Alipanahi) are shown for each of the 39 cell types found in six tissues in the anterior segment of the eye³⁶. Traits (rows) and cell types (columns) were clustered based on hierarchical 1391 1392 clustering of the euclidean distance between GWAS locus set cell type-specificity enrichment 1393 scores. Red rings: experiment-wide significant (Benjamini Hochberg (BH) FDR<0.1); Yellow rings: 1394 tissue-wide significant (BH FDR<0.1); Grey rings: nominal significant (P<0.05). b,d,e, Cell type 1395 specificity fold-enrichment (x-axis) in the different anterior segment cell types ranked in descending 1396 order for the POAG European subset (**b**), POAG cross-ancestry (**d**), and IOP (**e**) GWAS locus sets. 1397 Error bars: 95% confidence intervals. Red: tissue-wide significant (FDR<0.1); Grey: nominal 1398 significant (P<0.05); Blue: non-significant (P≥0.05). c,h, Differential gene expression (log₂(Fold-1399 change), y axis) in the most strongly enriched cell type compared to all other cell types is shown 1400 for the set of genes (x axis) driving the enrichment signal of the POAG European GWAS loci in 1401 ciliary fibroblasts (c) and the IOP GWAS loci in pericytes (cluster 2) (h). Vertical dashed line 1402 represents log₂(Fold-change) of 0.375 (FC=1.3) and FDR<0.1 that was used as the cell type-1403 specificity enrichment cutoff. Asterisks denote genes in IOP loci not associated with POAG risk (h). 1404 f-g, Heatmap of fraction of genes that overlap between the e/sGenes driving the enrichment signal 1405 for top ranked cell types (P<0.05) in the anterior segment for POAG cross-ancestry (f) and IOP (g) 1406 GWAS loci. Numbers refer to the fraction of e/sGenes driving the cell type enrichment on each row 1407 that overlaps with the genes driving the cell type enrichment on the corresponding column. 1408 Hierarchical clustering was performed on both rows and columns using the euclidean distance 1409 between fractions. Red asterisks: tissue-wide BH FDR<0.1. i, Bubble map displaying the 1410 expression of the e/sGenes driving the IOP enrichment in pericytes across all cell types in the 1411 anterior segment. The colorbar represents gene expression z-scores computed by comparing each 1412 gene's average expression in a given cell type to its per cell type average expression across all 1413 types divided by the standard deviation of all cell type expression averages. Bubble size is 1414 proportional to the percentage of cells expressing the given gene (log(TPK+1)>1). Cell type 1415 abbreviations are described in Supplementary Table 38. 1416

- 1410
- 1417
- 1418



1452 Figure 7. Cell type enrichment of e/sQTL-mapped genes for POAG, IOP and related trait loci 1453 in retina, optic nerve head and surrounding tissues. a,b, Significance (circle size, -log10(P-1454 value)) and fold-enrichment (circle color) of the cell type specificity of GWAS locus sets for POAG 1455 cross-ancestry, POAR European subset, IOP, and physician (VCDR) and machine learning (ML)-1456 defined VCDR (VCDR ML Alipanahi) are shown for each of the 15 cell types found in retina (a) 1457 and 36 cell types in optic nerve head (ONH), optic nerve (ON), peripapillary sclera, sclera and 1458 choroid (b). Traits (rows) and cell types (columns) were clustered based on hierarchical clustering 1459 of the euclidean distance between GWAS locus set cell type-specificity enrichment scores. Red 1460 rings: experiment-wide significant (BH FDR<0.1); Yellow rings: tissue-wide significant (BH 1461 FDR<0.1); Grey rings: nominal significant (P<0.05). c, Cell type specificity fold-enrichment (x-axis) 1462 in the ONH and surrounding tissue cell types ranked in descending order for the POAG cross-1463 ancestry GWAS locus set. d, Differential expression (log₂(Fold-change)) in astrocytes, the most 1464 strongly enriched cell type for POAG cross-ancestry GWAS loci in the ONH, compared to all other 1465 cell types in the posterior tissues is shown for the set of genes driving the POAG enrichment signal 1466 in astrocytes. Horizontal dashed line represents log₂(Fold-change) of 0.375 (FC=1.3) and FDR<0.1 1467 that was used as the cell type-specificity enrichment cutoff. e. The expression profile of the 1468 e/sGenes driving the POAG cross-ancestry enrichment signal in astrocytes is shown across all cell 1469 types in the ONH and surrounding tissues. Color represents z-scores computed by comparing each 1470 gene's average expression in a given cell type to the average expression across all cell types 1471 divided by its standard deviation of all cell type expression averages. Bubble size is proportional to 1472 the percentage of cells expressing the gene ($\log(TPK+1)>1$). **f**, LocusCompare plot of $-\log_{10}$ (Pvalue) of the POAG cross-ancestry GWAS meta-analysis relative to -log10(P-value) of a retina eQTL 1473 1474 acting on DGKG that significantly colocalized with the POAG GWAS locus rs56233426 1475 (chr3 186411027 G A). DGKG is the strongest astrocyte-specific gene driving the cell type 1476 enrichment signal for POAG loci. Points are color-coded based on LD (r²) relative to the eVariant 1477 with the highest colocalization posterior probability (CLPP=0.93). The red arrow is pointing to the 1478 lead POAG GWAS variant. Cell type abbreviations are described in Supplementary Table 38.

1479 Table 1. List of high-confidence colocalizing expression and splicing QTLs with POAG and

1480 **IOP GWAS loci**.

		GWAS effect (OR	# e/sGenes tested per	# significantly colocalizing e/sGenes with	Colocalizing e/sGenes with eCAVIAR and	Significantly	Nearest		
GWAS locus	RS ID	or beta)	locus	eCAVIAR or enloc	enloc and significant with MR	Retina eQTL	Gene	Significan	t in GWAS:
			PC	AG cross-ancestry	GWAS	-		IOP	POAG European
chr1:171636338:G:A	rs74315329	5.46957	24	1	PIGC (s)	-	-	-	-
chr1:165768467:G:C	rs2790053	1.35026	13	2	TMCO1 (e,s)	-	+	TMCO1	TMCO1
chr9:22051671:G:C	rs944801	1.2663	26	3	CDKN2B-AS1 (s)	-	+	-	CDKN2B-AS1
chr4:7902636:G:A	rs938604	0.866407	27	2	AFAP1 (e)	-	+	AFAP1	-
chr17:10127866:G:A	rs9913911	1.14912	30	1	GAS7 (e)	-	+	GAS7	GAS7
chr9:126628521:C:T	rs3829849	0.87529	11	4	LMX1B (e)	-	+	LMX1B	LMX1B
chr7:116522252:T:A	rs10257125	0.890921	18	2	CAV2 (e,s)	-	-	CAV2	CAV2
chr11:86657064:C:T	rs10792871	1.12142	15	4	PRSS23 (e), ME3 (e)	-	+	PRSS23, ME3	PRSS23, ME3
chr9:133255801:C:T	rs8176749	1.10186	18	1	ABO (e)	-	+	ABO	-
chr15:73928957:C:T	rs1550437	0.913657	72	2	LOXL1 (e,s)	-	+	-	LOXL1
chr3:188349165:G:T	rs6787621	0.92626	7	1	LPP (e,s)	-	+	LPP	-
chr22:28712241:G:A	rs5752776	0.926631	27	5	TTC28 (e)	-	+	-	TTC28
chr2:12811195:C:T	rs12623251	0.932021	11	1	TRIB2 (e)	-	+	-	TRIB2
chr15:57261634:T:A	rs2431023	1.07026	16	2	ZNF280D (e), TCF12 (e)	-	+	-	ZNF280D, TCF12
chr11:130412183:C:T	rs2875238	0.935289	7	2	RP11-121M22.1 (e,s), ADAMTS8 (e)	-	+	-	-
chr7:134835770:C:A	rs10237321	0.94535	29	1	CALD1 (e)	-	+	-	-
chr6:134051012:G:C	rs2811688	0.946296	3	3	SLC2A12 (e), TBPL1 (e)	SLC2A12	+	-	SLC2A12, TBPL1
				IOP GWAS				POAG European	POAG cross-ancestry
chr1:165715441:C:T	rs116089225	-0.744	29	3	TMCO1 (e)	-	+	TMCO1	TMCO1
chr14:74498200:C:T	rs74384554	0.417	70	4	NPC2 (e)	NPC2	-	-	NPC2
chr17:10127866:G:A	rs9913911	0.231	3	1	GAS7 (e)	-	+	GAS7	GAS7
chr7:116511284:C:T	rs10281637	-0.225	13	3	CAV2 (e), CAV1 (e)	-	+	CAV2	CAV2
chr11:120422429:G:A	rs11217863	-0.224	17	2	ARHGEF12 (e,s)	-	+	ARHGEF12	ARHGEF12
chr1:218937686:C:A	rs73103335	0.206	11	2	LYPLAL1-AS1 (e,s)	-	+	-	-
chr5:108710999:G:A	rs73220177	0.165	9	2	LINC01023 (e)	-	-	-	-
chr22:19854787:G:A	rs17534001	0.16	26	4	TXNRD2 (e,s)	-	+	TXNRD2	TXNRD2
chr6:170146547:G:T	rs59020521	-0.148	18	2	RP11-302L19.3 (e)	-	-	-	RP11-302L19.3
chr22:29224336:C:A	rs9608740	-0.141	40	3	EMID1 (e,s)	-	+	EMID1	-
chr2:238402728:C:T	rs57435966	0.132	25	3	TRAF3IP1 (e)	-	+	-	-
chr11:16989629:C:A	rs4141194	-0.131	18	5	NCR3LG1 (e), KCNJ11 (e,s), NUCB2 (s)	NCR3LG1	-	-	NUCB2
chr11:86699199:C:T	rs2433414	-0.128	22	6	ME3 (e)	-	+	ME3	ME3
chr11:47253513:G:A	rs10838681	-0.124	56	12	PTPRJ (e)	-	-	-	-
chr3:50162314:G:A	rs11710277	-0.12	117	14	LSMEM2 (e)	-	-	-	-
chr15:61659036:C:T	rs4775427	-0.111	7	5	RP11-507B12.1 (e), RP11-507B12.2 (e),	-	-	RP11-507B12.1, RP11-	RP11-507B12.1, RP11-
					RP11-16217.1 (e)			507B12.2, RP11-	507B12.2, RP11-
chr14:52920118:G:C	rs8009633	0.11	12	2	FERMT2 (e,s)	-	+	-	-
chr2:101031432:G:A	rs55771809	0.109	17	3	TBC1D8 (s)	TBC1D8	+	-	-
chr7:116171382:C:A	rs2896175	0.108	12	4	TES (e)	-	-	-	-
chr16:89752083:C:T	rs3743860	0.102	57	14	ZNF276 (e,s), SPIRE2 (e), FANCA (e,s),	-	+	-	-
					VPS9D1 (e)				
chr11:78374959:C:T	rs10793308	0.098	25	4	NARS2 (e,s), USP35 (e)	-	-	-	-
chr11:86789159:C:T	rs11606902	-0.098	12	4	PRSS23 (e), ME3 (e)	PRSS23	+	PRSS23, ME3	PRSS23, ME3
chr1:112639117:G:C	rs61818802	-0.097	14	4	MOV10 (e), RHOC (e)	-	-	-	MOV10
chr3:50143702:G:T	rs2526385	0.096	116	16	LSMEM2 (e)	-	-	-	-
chr22:37788844:C:T	rs6000889	0.094	47	10	GCAT (e,s)	-	-	-	GCAT
chr7:11644065:C:T	rs1635182	-0.094	4	1	THSD7A (e)	-	+	-	THSD7A
chr3:188343926:C:T	rs4132172	0.093	4	2	LPP (e,s)	-	+		LPP
chr17:46758936:C:T	rs9912530	0.091	58	14	WNT3 (e)	-	+	WNT3	-
chr1:37627051:C:T	rs4074961	-0.089	17	5	GNL2 (e,s), MEAF6 (e), DNALI1 (s)	MEAF6	-	GNL2, MEAF6, DNALI1	
chr10:80411803:C:T	rs6585986	-0.084	37	4	TSPAN14 (s), ANXA11 (e)	-	-	-	-
chr13:75683130:G:C	rs9544022	-0.081	9	2	LM07 (s)	-	+	LM07	-
chr2:217802649:T:A	rs3791979	-0.081	9	2	TNS1 (e,s)		+	-	-
chr11:817786:C:T	rs10902223	0.079	49	18	PIDD1, CRACR2B, PNPLA2, CHID1	-	-	-	-
chr10:92670768:G:A	rs9419741	-0.077	19	4	HHEX (e)	-	+	-	-
chr1:31726197:G:C	rs945211	-0.073	28	5	COL16A1 (e,s)	-	-	-	-
chr6:39895441:G:A	rs3004063	0.071	9	3	MOCS1 (e), RP11-61/13.3 (e,s), DAAM2 (s)	-	+	-	-
chr17:49264218:C:T	rs9899665	-0.069	31	2	GNGT2 (e)	-	-	-	

1482 Table lists target genes of expression and splicing QTLs (e/sGenes) that were significant based

1483 on colocalization analysis with both eCAVIAR (CLPP>0.01) and *enloc* (RCP>0.1) and Mendelian

1484 Randomization (MR) analysis (FDR<0.05) for POAG and/or IOP GWAS loci.

1485

1481

1486 **References**

- Tham, Y.-C. *et al.* Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* **121**, 2081–2090 (2014).
- 1490 2. Weinreb, R. N. *et al.* Primary open-angle glaucoma. *Nat Rev Dis Primers* **2**, 16067 (2016).
- Leske, M. C. *et al.* Predictors of long-term progression in the early manifest glaucoma trial.
 Ophthalmology **114**, 1965–1972 (2007).
- Kwon, Y. H., Fingert, J. H., Kuehn, M. H. & Alward, W. L. M. Primary open-angle glaucoma.
 N. Engl. J. Med. 360, 1113–1124 (2009).
- 1495 5. Kim, J. *et al.* Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity 1496 and induces glaucoma. *J. Clin. Invest.* **127**, 3877–3896 (2017).
- Costagliola, C. *et al.* How many aqueous humor outflow pathways are there? *Surv. Ophthalmol.* **65**, 144–170 (2020).
- Anderson, D. R., Drance, S. M., Schulzer, M. & Collaborative Normal-Tension Glaucoma
 Study Group. Natural history of normal-tension glaucoma. *Ophthalmology* **108**, 247–253
 (2001).
- B. Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci
 with consistent effect across ancestries. *Nat. Commun.* **12**, 1258 (2021).
- 1504 9. Khawaja, A. P. *et al.* Genome-wide analyses identify 68 new loci associated with intraocular
 pressure and improve risk prediction for primary open-angle glaucoma. *Nature Genetics* vol.
- 1506 50 778–782 Preprint at https://doi.org/10.1038/s41588-018-0126-8 (2018).
- 1507 10. MacGregor, S. *et al.* Genome-wide association study of intraocular pressure uncovers new
 pathways to glaucoma. *Nature Genetics* vol. 50 1067–1071 Preprint at
- 1509 https://doi.org/10.1038/s41588-018-0176-y (2018).
- 151011. Gao, X. R. *et al.* Genome-wide association analyses identify new loci influencing intraocular1511pressure. *Human Molecular Genetics* vol. 27 2205–2213 Preprint at
- 1512 https://doi.org/10.1093/hmg/ddy111 (2018).
- 1513 12. Alipanahi, B. *et al.* Large-scale machine-learning-based phenotyping significantly improves
- 1514 genomic discovery for optic nerve head morphology. *Am. J. Hum. Genet.* 108, 1217–12301515 (2021).
- 1516 13. Springelkamp, H. *et al.* New insights into the genetics of primary open-angle glaucoma
- 1517 based on meta-analyses of intraocular pressure and optic disc characteristics. *Hum. Mol.*
- 1518 *Genet.* **26**, 438–453 (2017).

- 14. Lu, Y. *et al.* Common genetic variants near the Brittle Cornea Syndrome locus ZNF469
 influence the blinding disease risk factor central corneal thickness. *PLoS Genet.* 6,
 e1000947 (2010).
- 15. Vitart, V. *et al.* New loci associated with central cornea thickness include COL5A1, AKAP13
 and AVGR8. *Hum. Mol. Genet.* **19**, 4304–4311 (2010).
- 16. Hoehn, R. *et al.* Population-based meta-analysis in Caucasians confirms association with
 COL5A1 and ZNF469 but not COL8A2 with central corneal thickness. *Hum. Genet.* 131,
 1783–1793 (2012).
- 1527 17. Gao, X. *et al.* A genome-wide association study of central corneal thickness in Latinos.
 1528 *Invest. Ophthalmol. Vis. Sci.* 54, 2435–2443 (2013).
- 1529 18. Iglesias, A. I. *et al.* Cross-ancestry genome-wide association analysis of corneal thickness
 1530 strengthens link between complex and Mendelian eye diseases. *Nat. Commun.* 9, 1864
 1531 (2018).
- 1532 19. Gao, X. *et al.* Genome-wide association study identifies WNT7B as a novel locus for central
 1533 corneal thickness in Latinos. *Hum. Mol. Genet.* 25, 5035–5045 (2016).
- 1534 20. Fan, B. J. *et al.* Family-Based Genome-Wide Association Study of South Indian Pedigrees
 1535 Supports WNT7B as a Central Corneal Thickness Locus. *Invest. Ophthalmol. Vis. Sci.* 59,
 1536 2495–2502 (2018).
- 1537 21. Ivarsdottir, E. V. *et al.* Sequence variation at ANAPC1 accounts for 24% of the variability in
 1538 corneal endothelial cell density. *Nat. Commun.* **10**, 1284 (2019).
- Simcoe, M. J., Khawaja, A. P., Hysi, P. G., Hammond, C. J. & UK Biobank Eye and Vision
 Consortium. Genome-wide association study of corneal biomechanical properties identifies
 over 200 loci providing insight into the genetic etiology of ocular diseases. *Hum. Mol. Genet.* **29**, 3154–3164 (2020).
- 1543 23. Han, X. *et al.* Automated AI labeling of optic nerve head enables insights into cross-ancestry
 1544 glaucoma risk and genetic discovery in >280,000 images from UKB and CLSA. *Am. J. Hum.*1545 *Genet.* 108, 1204–1216 (2021).
- 1546 24. Gamazon, E. R. *et al.* Using an atlas of gene regulation across 44 human tissues to inform
 1547 complex disease- and trait-associated variation. *Nat. Genet.* **50**, 956–967 (2018).
- 1548 25. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
 1549 disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
- 1550 26. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human
 1551 tissues. *Science* 369, 1318–1330 (2020).

- 1552 27. Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated
 1553 with age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).
- 1554 28. Strunz, T. *et al.* A mega-analysis of expression quantitative trait loci in retinal tissue. *PLoS*1555 *Genet.* 16, e1008934 (2020).
- 1556 29. Orozco, L. D. *et al.* Integration of eQTL and a single-cell atlas in the human eye identifies
 1557 causal genes for age-related macular degeneration. *Cell Rep.* **30**, 1246-1259.e6 (2020).
- 1558 30. Liu, B. *et al.* Genetic analyses of human fetal retinal pigment epithelium gene expression
 1559 suggest ocular disease mechanisms. *Commun. Biol.* 2, 186 (2019).
- 1560 31. Yan, W. *et al.* Cell Atlas of The Human Fovea and Peripheral Retina. *Sci. Rep.* **10**, 9802
 1561 (2020).
- 1562 32. Dharmat, R., Kim, S., Li, Y. & Chen, R. Single-Cell Capture, RNA-seq, and Transcriptome
 1563 Analysis from the Neural Retina. *Methods Mol. Biol.* 2092, 159–186 (2020).
- 1564 33. Liang, Q. *et al.* A multi-omics atlas of the human retina at single-cell resolution. *Cell Genom.*1565 3, 100298 (2023).
- 1566 34. van Zyl, T. *et al.* Cell atlas of aqueous humor outflow pathways in eyes of humans and four
 1567 model species provides insight into glaucoma pathogenesis. *Proc. Natl. Acad. Sci. U. S. A.*1568 **117**, 10339–10349 (2020).
- 1569 35. Patel, G. *et al.* Molecular taxonomy of human ocular outflow tissues defined by single-cell
 1570 transcriptomics. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 12856–12867 (2020).
- 1571 36. van Zyl, T. *et al.* Cell atlas of the human ocular anterior segment: Tissue-specific and shared
 1572 cell types. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2200914119 (2022).
- 1573 37. Monavarfeshani, A. *et al.* Transcriptomic Analysis of the Ocular Posterior Segment
 1574 Completes a Cell Atlas of the Human Eye. *bioRxiv* (2023) doi:10.1101/2023.04.26.538447.
- 1575 38. Eraslan, G. *et al.* Single-nucleus cross-tissue molecular reference maps toward 1576 understanding disease gene function. *Science* **376**, eabl4290 (2022).
- 1577 39. Rouhana, J., J. Wang, G. Eraslan, S. Anand, A. Hamel, B. Cole, A. Regev, F. Aguet, K.
- 1578 Ardlie, and A. V. Segrè. ECLIPSER: identifying causal cell types and genes for complex
- traits through single cell enrichment of e/sQTL-mapped genes in GWAS loci. *BioRxiv* (2021)
 doi:10.1101/2021.11.24.469720.
- 40. Marchal, C. *et al.* High-resolution genome topology of human retina uncovers super
 enhancer-promoter interactions at tissue-specific and multifactorial disease loci. *Nat. Commun.* 13, 5827 (2022).
- 41. Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am. J. Hum. Genet.* **99**, 1245–1260 (2016).

- 42. Wen, X., Pique-Regi, R. & Luca, F. Integrating molecular QTL data into genome-wide
 genetic association analysis: Probabilistic assessment of enrichment and colocalization. *PLoS Genet.* 13, e1006646 (2017).
- 43. Thomson, B. R. *et al.* Angiopoietin-1 is required for Schlemm's canal development in mice
 and humans. *J. Clin. Invest.* **127**, 4421–4436 (2017).
- 44. Wiggs, J. L. *et al.* Common variants at 9p21 and 8q22 are associated with increased
 susceptibility to optic nerve degeneration in glaucoma. *PLoS Genet.* 8, e1002654 (2012).
- 45. Collantes, E. R. A. *et al.* EFEMP1 rare variants cause familial juvenile-onset open-angle
 glaucoma. *Hum. Mutat.* 43, 240–252 (2022).
- 46. Wiggs, J. L. & Pasquale, L. R. Genetics of glaucoma. *Hum. Mol. Genet.* 26, R21–R27
 (2017).
- 47. Lewczuk, K., Jabłońska, J., Konopińska, J., Mariak, Z. & Rękas, M. Schlemm's canal: the
 outflow "vessel." *Acta Ophthalmol.* (2021) doi:10.1111/aos.15027.
- 48. Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at GWAS
 loci. *Genome Biol.* 22, 49 (2021).
- 49. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex
 trait gene targets. *Nat. Genet.* 48, 481–487 (2016).
- 1603 50. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in
 1604 Mendelian randomization studies. *Hum. Mol. Genet.* 27, R195–R208 (2018).
- 1605 51. Zuber, V. *et al.* Combining evidence from Mendelian randomization and colocalization:
- 1606 Review and comparison of approaches. *Am. J. Hum. Genet.* **109**, 767–782 (2022).
- 1607 52. Hukku, A. *et al.* Probabilistic colocalization of genetic variants from complex and molecular
 1608 traits: promise and limitations. *Am. J. Hum. Genet.* **108**, 25–35 (2021).
- 1609 53. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
 1610 colocalisation analyses. *PLoS Genet.* **16**, e1008720 (2020).
- 1611 54. GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature*1612 550, 204–213 (2017).
- 1613 55. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N.*1614 *Engl. J. Med.* **373**, 895–907 (2015).
- 1615 56. Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nature*1616 **593**, 238–243 (2021).
- 1617 57. Cao, J. *et al.* Joint profiling of chromatin accessibility and gene expression in thousands of
 1618 single cells. *Science* 361, 1380–1385 (2018).

- 1619 58. Mackay, D. S., Bennett, T. M. & Shiels, A. Exome Sequencing Identifies a Missense Variant
 1620 in EFEMP1 Co-Segregating in a Family with Autosomal Dominant Primary Open-Angle
 1621 Glaucoma. *PLoS One* **10**, e0132529 (2015).
- 1622 59. Lim, S.-H. *et al.* CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma 1623 patients in the United States. *Am. J. Ophthalmol.* **155**, 508-517.e5 (2013).
- 1624 60. Fuchshofer, R. & Tamm, E. R. The role of TGF-β in the pathogenesis of primary open-angle
 1625 glaucoma. *Cell Tissue Res.* 347, 279–290 (2012).
- 1626 61. Scerbo, P. & Monsoro-Burq, A. H. The vertebrate-specific VENTX/NANOG gene empowers
 1627 neural crest with ectomesenchyme potential. *Sci Adv* 6, eaaz1469 (2020).
- 1628 62. Kumar, S., Kumar, V., Li, W. & Kim, J. Ventx Family and Its Functional Similarities with
 1629 Nanog: Involvement in Embryonic Development and Cancer Progression. *Int. J. Mol. Sci.* 23,
 1630 (2022).
- 1631 63. Fadini, G. P. *et al.* Reduced endothelial progenitor cells and brachial artery flow-mediated
 1632 dilation as evidence of endothelial dysfunction in ocular hypertension and primary open1633 angle glaucoma. *Acta Ophthalmol.* 88, 135–141 (2010).
- 1634 64. Su, W.-W. *et al.* Glaucoma is associated with peripheral vascular endothelial dysfunction.
 1635 *Ophthalmology* **115**, 1173-1178.e1 (2008).
- 1636 65. Green, K. J., Getsios, S., Troyanovsky, S. & Godsel, L. M. Intercellular junction assembly,
 1637 dynamics, and homeostasis. *Cold Spring Harb. Perspect. Biol.* 2, a000125 (2010).
- 1638 66. Pattabiraman, P. P., Epstein, D. L. & Rao, P. V. Regulation of Adherens Junctions in
- 1639 Trabecular Meshwork Cells by Rac GTPase and their influence on Intraocular Pressure. *J.*1640 Ocul. Biol. Dis. Infor. 1, (2013).
- 1641 67. Gould, D. B., Smith, R. S. & John, S. W. M. Anterior segment development relevant to
 1642 glaucoma. *Int. J. Dev. Biol.* 48, 1015–1029 (2004).
- 1643 68. Ronen E. Mukamel, Robert E. Handsaker, Maxwell A. Sherman, Alison R. Barton, Margaux
 1644 L. A. Hujoel, Steven A. McCarroll, Po-Ru Loh. Repeat polymorphisms in non-coding DNA
 1645 underlie top genetic risk loci for glaucoma and colorectal cancer. *bioRxiv* (2022)
- 1646 doi:10.1101/2022.10.11.22280955.
- 1647 69. Pasquale, L. R. *et al.* CDKN2B-AS1 genotype-glaucoma feature correlations in primary
 1648 open-angle glaucoma patients from the United States. *Am. J. Ophthalmol.* 155, 342-353.e5
 1649 (2013).
- 1650 70. Kim, B. J. & Scott, D. A. RERE deficiency causes retinal and optic nerve atrophy through
 1651 degeneration of retinal cells. *Dev. Dyn.* 250, 1398–1409 (2021).

- 1652 71. Wang, H. et al. Physiological function of myocilin and its role in the pathogenesis of
- 1653 glaucoma in the trabecular meshwork (Review). *Int. J. Mol. Med.* **43**, 671–681 (2019).
- 1654 72. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
 1655 association summary statistics. *Nat. Genet.* 47, 1228–1235 (2015).
- 1656 73. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
 1657 annotation of genetic associations with FUMA. *Nat. Commun.* 8, 1826 (2017).
- 1658 74. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes across
- 1659the human body by integration of single-cell profiles and human genetics. *bioRxiv*16602021.03.19.436212 (2021) doi:10.1101/2021.03.19.436212.
- 1661 75. Slowikowski, K., Hu, X. & Raychaudhuri, S. SNPsea: an algorithm to identify cell types,
 1662 tissues and pathways affected by risk loci. *Bioinformatics* **30**, 2496–2497 (2014).
- 1663 76. Calderon, D. *et al.* Inferring Relevant Cell Types for Complex Traits by Using Single-Cell
 1664 Gene Expression. *Am. J. Hum. Genet.* **101**, 686–699 (2017).
- 1665 77. Stamer, W. D. & Acott, T. S. Current understanding of conventional outflow dysfunction in
 1666 glaucoma. *Curr. Opin. Ophthalmol.* 23, 135–143 (2012).
- 1667 78. Alarcon-Martinez, L. *et al.* Pericyte dysfunction and loss of interpericyte tunneling nanotubes
 promote neurovascular deficits in glaucoma. *Proc. Natl. Acad. Sci. U. S. A.* **119**, (2022).
- 1669 79. Wang, R., Seifert, P. & Jakobs, T. C. Astrocytes in the Optic Nerve Head of Glaucomatous
 1670 Mice Display a Characteristic Reactive Phenotype. *Invest. Ophthalmol. Vis. Sci.* 58, 924–
 1671 932 (2017).
- 1672 80. Zhao, X., Sun, R., Luo, X., Wang, F. & Sun, X. The Interaction Between Microglia and
 1673 Macroglia in Glaucoma. *Front. Neurosci.* **15**, 610788 (2021).
- 1674 81. Shinozaki, Y. & Koizumi, S. Potential roles of astrocytes and Müller cells in the pathogenesis
 1675 of glaucoma. *J. Pharmacol. Sci.* 145, 262–267 (2021).
- 1676 82. Tovar-Vidales, T., Wordinger, R. J. & Clark, A. F. Identification and localization of lamina 1677 cribrosa cells in the human optic nerve head. *Exp. Eye Res.* **147**, 94–97 (2016).
- 1678 83. Lopez, N. N., Clark, A. F. & Tovar-Vidales, T. Isolation and characterization of human optic
 1679 nerve head astrocytes and lamina cribrosa cells. *Exp. Eye Res.* **197**, 108103 (2020).
- 1680 84. Strickland, R. G., Garner, M. A., Gross, A. K. & Girkin, C. A. Remodeling of the lamina
 1681 cribrosa: Mechanisms and potential therapeutic approaches for glaucoma. *Int. J. Mol. Sci.*
- **1682 23**, 8068 (2022).
- 1683 85. Calkins, D. J. Critical pathogenic events underlying progression of neurodegeneration in
 1684 glaucoma. *Prog. Retin. Eye Res.* **31**, 702–719 (2012).

- 1685 86. Venkataraman, S. T., Flanagan, J. G. & Hudson, C. Vascular reactivity of optic nerve head 1686 and retinal blood vessels in glaucoma--a review. *Microcirculation* **17**, 568–581 (2010).
- 1687 87. Tamm, E. R., Ethier, C. R. & Lasker/IRRF Initiative on Astrocytes and Glaucomatous
 1688 Neurodegeneration Participants. Biological aspects of axonal damage in glaucoma: A brief
 1689 review. *Exp. Eye Res.* **157**, 5–12 (2017).
- 1690 88. Paula, J. S., O'Brien, C. & Stamer, W. D. Life under pressure: The role of ocular cribriform
 1691 cells in preventing glaucoma. *Exp. Eye Res.* **151**, 150–159 (2016).
- 1692 89. Zeng, H.-L. & Shi, J.-M. The role of microglia in the progression of glaucomatous
 1693 neurodegeneration- a review. *Int. J. Ophthalmol.* **11**, 143–149 (2018).
- 1694 90. Kim-Hellmuth, S., Aguet, F. & Oliva, M. Cell type–specific genetic regulation of gene
 1695 expression across human tissues. (2020).
- 1696 91. van der Wijst, M. et al. The single-cell eQTLGen consortium. Elife 9, (2020).
- 1697 92. Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nat. Genet.* **50**,
 1698 151–158 (2018).
- 1699 93. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan
 1700 results. *Bioinformatics* 26, 2336–2337 (2010).
- 1701 94. Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. *Proc. Natl.*1702 *Acad. Sci. U. S. A.* **100**, 9440–9445 (2003).
- 95. Gamazon, E. R., Huang, R. S., Dolan, M. E., Cox, N. J. & Im, H. K. Integrative genomics:
 quantifying significance of phenotype-genotype relationships from multiple sources of highthroughput data. *Front. Genet.* **3**, 202 (2012).
- 1706 96. Zheng-Bradley, X. *et al.* Alignment of 1000 Genomes Project reads to reference assembly
 1707 GRCh38. *Gigascience* 6, 1–8 (2017).
- 1708 97. Smith, G. D. & Ebrahim, S. "Mendelian randomization": can genetic epidemiology contribute
 1709 to understanding environmental determinants of disease? *Int. J. Epidemiol.* 32, 1–22 (2003).
- 1710 98. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing
- 1711 Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734–1739 1712 (2017).
- Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for
 Mendelian randomization. *Stat. Methods Med. Res.* 26, 2333–2355 (2017).
- 1715 100. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with
- 1716 multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658–665 (2013).

- 1717 101. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
- Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
- 102. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
 instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.*44, 512–525 (2015).
- 1723 103. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy
 1724 in causal relationships inferred from Mendelian randomization between complex traits and
 1725 diseases. *Nat. Genet.* **50**, 693–698 (2018).
- 1726 104. Quinlan, A. R. BEDTools: The Swiss-army tool for genome feature analysis. *Curr. Protoc.*1727 *Bioinformatics* 47, 11.12.1-34 (2014).
- 105. Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes
 and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol.* 16, 278
 (2015).
- 1731 106. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated
 1732 genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* 49, D1311–
 1733 D1320 (2021).
- 1734 107. Watanabe, K., Umićević Mirkov, M., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma, D. 1735 Genetic mapping of cell type specificity for complex traits. *Nat. Commun.* **10**, 3222 (2019).
- 1736 108. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set 1737 analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
- 109. Pollack, S. *et al.* Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using
 Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. *Diabetes* 68,
 441–456 (2019).
- 1741 110. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or
- 1742 without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).